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(expressed  on 13 December 1996)
Terms of reference
To advise on the acceptability from the public health point of view of certain substances  in natural
mineral waters. The substances  the Cornmittee is asked to consider are those natural constituents
for which the levels requested by the European industry (') are above the levels in the drinking
water directive (') or in its proposed amendment  (3).
Background
Directive 8017771EEC (') on natural mineral waters defines 'natural mineral water' as:
'...microbiologically  wholesome water originating  in an underground  water table or
deposit and emerging from a spring tapped at one or more natural or bore exits.
Natural mineral  yvater can be distinguishedfrorn ordinary drinking water, notably:
.  by its nature, which is characterised by its mineral  conlent, trsce elements and
other constituents;
'  by its original state.'
The directive states that 'natural mirreral  waters  are protected  from all risk of pollution in order to
preserve intact these characteristics'.  However, this directive  of  1980 does not lay down
individual limits for the minerals, trace elements  or contaminants that may be found in natural
mineral waters.
The Committee  was informed that a proposal (') to update Directive  80ll77lEEC was in the
process of adoption to take into account scientific and technical progress  and the mandate from
the European  Council for rationalising  the directive.  Under this new directive ('), the SCF must
(')  The European organisation  of producers  of narural  mineral  waters (GESEM-LINESEM).
O  Council Directive 80/778/EEC  of l5 July  1990 relating to the quality of water intended  for human consumption  (OI L 229,30.8.1980,
p. l 1).
(.)  Froposal  for a Council directive conceming the quality  of water intended  for human  consumption (COM(94)  612 final, OJ C 131,
30.5,1995, p.5).
C)  Council Directive  8Ol7'77 iEEC of I 5 July  1 990 on the approximation of the laws of the Member States  relating to the exploitation and
marketing  of natural  mineral  waters (OJ L 229, 30.8.1980,  p. 1).
(')  European  Commission Proposal  for a European  Parliament and Council  directive  arnending  Council  Directive  \Oll'|'llEEC  onthe
approximation of the laws of the Member States  relating to the exploitation  and marketing of natural  mineral waters  (COM(94)  423
fnal, 9410235  (COD), OJ C t, 4.1.D9a,  p. 22).
(')  Directive g6/70lEC of the European  Parliament  and of the Council of 28 October 1996 amending  Council Directive  80|777/EEC  on
the approximation of the laws of the Member States  relating to the exploitation  and marketing  of natural  mineral waters  (OJ L 299,
23.11 .1996. p. 26).
Reports  of the Scientific Committee for Food (43rd series)be consulted in questions  relating to public health. The European industry (t) presented  to the
Commission  a list of proposed limits for these substances which included a number which
exceeded the limits in Directive 80/778|EEC  () or in its proposed amendment(3).
Evaluation
Introduction
In preparing this report, the Committee  has made use of reviews such as the SCF report on
nutrient and energy intakes for the European  Community  (27), the WHO guidelines for drinking
water qualrty (31,32,34),  IARC and US-NRC, US-ATSDR,  Ecetoc and RIVM reports  and recent
papers.
The Committee was provided with information on the consumption of natural mineral waters in
the Community.  However,  this information does not allow estimation of intakes by high level
consumers of natural mineral waters. Some natural  mineral waters  are increasingly consumed  as a
replacement for tap water. In the absence of other data, the Committee considered that the
conventional value of 2 litres per day and per person for the consumption figure,  as used by the
EU and WHO for risk assessments  relating to drinking water, should also be applied to natural
mineral waters. The Committee is aware that this is a conservative  approach.
In making its nsk assessment,  the Committee has recognised  that drinking water is not the sole
dietary source of human exposure to the substances  under consideration.  For boron and
manganese,  the Committee has, in the absence of reliable exposure  data, used the WHO default
value of 10 %, (31) as the proportion  of the TDI (or equivalent value established  in this opinion)
which can be allocated to natural mineral waters. This approach  could not be applied to arsenic
which has been classified  by the Intemational Agency for Research on Cancer (IARC) as a human
carcinogen  (16). For barium and fluoride the evaluation is based on epidemiological  data derived
from studies involving  consumption  of drinking water containing known levels of these elements.
Individual substances
1. Arsenic (As)
Evaluation
Inorganic arsenic is an established  carcinogen  able to induce primary skin cancer and has been
classified by IARC 1987 (16) in Group 1 (carcinogenic to humans). So far it has been found
negative in animal carcinogenicity bioassays with one exception, but positive in tumour
promotion  studies. It has been found essentially non-mutagenic at gene level, but able to induce
chromosomal  aberrations and micronuclei in a variety of mammalian cells, including  human cells.
The mechanism of  arsenic carcinogenic  activity has not yet been clarified. Recent
Reports of the Scientific  Committee  for Food (43rd  series)epidemiological  studies (7, 28, 3) seem to suggest  that the carcinogenicity of arsenic requires  the
presence  of other carcinogenic  agents  such as cigarette  smoke.
All these facts seem to suggest that arsenic is an indirect  carcinogen,  with promoting  and/or co-
carcinogenic activity. The lack of knowledge of the precise  mechanism of carcinogenic activity
and the known problems in applying mathematical models  makes the cancer-risk assessment  for
arsenic very difficult.  Based on the increased incidence  of skin cancer observed in Taiwan and by
using a muitistage  model, WHO (32) has calculated  that an excess lifetime skin cancer risk of l0-5
is associated  to a concentration  of 0.17 mgil in drinking water. This value may, however,
overestimate the actual risk due to a number of factors, among which is the possible indirect
mechanism  of arsenic carcinogenicity. In order to reduce the concentration of arsenic in drinking
wator, WHO  has established a provisional  guideline value of 10 pgll. This value is in line with the
proposed  amendment of the drinking water directive (3) but it is below the maximum  admissible
concentration  of 5Opgil in the existing directive (2).
Conclusion
In consideration of the fact that inorganic  arsenic is an established  human carcinogen,  exposure
should be as low as possible. For the time being an upper level of 10 prgil in natural mineral
waters  seems reasonable and is in line with the proposed  amendment  (3) to the existing drinking
water directive.
2. Barium @a)
Evaluation
Barium is not considered  to be an essential  element. Soluble salts of barium are known to be
toxic. The acute toxic oral dose of barium chloride for humans is reported to be 0.2{.5 g and
doses above 3 g are lethal.
Sub-chronic  studies following oral exposure  have been carried out in rats. The most relevant
adverse  effect reported was a rise in systolic blood pressure when barium was given in the
drinking  water at 100 mgA (22,23). Although even 10 mg/l induced some less marked increases
in blood pressure,  being only occasionally  significant, a no-adverse-effect level of 0'5 mg/kg
b.w./day was derived frorn that concentration, because the increases were deemed small enough
not to constitute  an adverse effect (34).
In a controlled human study, daily doses of barium up to 15 mg did not show effects on blood
pressure or on the cardiovascular system (36). One retrospective epidemiological  study in some
communities in Illinois (USA) resulted in significantly higher age-adjusted  death rates for 'all
cardiovascular diseases' and 'heart disease'  in the areas with high barium  levels in the drinking
water (2-10 mgil) compared  with low barium communities (< 0.2 mgll) (5). However, this study
was difficult to interpret  and in a similar, better controlled, study by the same authors it was
concluded  that levels of barium in drinking water of 7.3 mg/l do not significantly elevate blood
pressure levels in adult males or females (6).
of the Scientific  Committee  for FoodConclusion
Considering that the concentration of 7,3 mg/l drinking water does not affect blood pressure  or
incidence of cardiovascular  diseases in humans and applying an uncertainty factor of l0 to
account for intra-human  variations, an upper level of 1 mg/l in natural mineral  waters  appears to
be acceptable,
3. Fluoride (F)
Evaluation
In 1992 the SCI] concluded  that there does not appear to be a specific physiological  requirement
for fluoride and no specific recommendations  were made (27). However, it was recognised  that
the element  is beneficial to dental health at low intakes while on the other hand fluoride excess
(fluorosis) is endemic in many parts of the world.
Fluoride has been subject to a series of acute, short-term, and long-term  studies,  but given the
limited  character of these animal studies, and the large body of data on the toxic effects of
fluoride in humans, the latter data have priority in the derivation of long-term tolerable intakes for
humans.
In humans,  acute toxic effects have been reported  at doses of 1-10 mdkg b.w. with values of 14-
l40mglkg b.w. being reported forthe acute lethal oral dose of soluble fluorides.  The long-term
adverse effect starts in its mild form at concentrations  within the 'beneficial' range with a mild
dental fluorosis  prevalence of 12-33 %o being reported for concentrations in drinking water of
0.9-1 .2 mgllitre.  The clinical picture of dental fluorosis in the mild form consists of the presence
of opaque white areas on the teeth and is normally  considered  as a cosmetic effect rather than an
adverse effect. Severe forms of this condition  occur already  at concentrations  of 5-7 mgllitre. In
such cases the tooth enamel can become brittle enough to fracture at incisal edges and cusp tips.
Climate  has been identified as a factor determining  the degree to which dental fluorosis will
develop. In areas with a temperate climate, manifest  dental fluorosis occurs at concentrations
above I.5-2.0 mg/litre  whereas in warmer areas, the same effect may be already  present at lower
concentrations i.e, 0.7 -1.2 mgllitre. This may be attributed  to greater water consumption  in
wafiner climates  (25, 9, 30, 29).
Skeletal  fluorosis consists of adverse changes in bone structure due to continuous deposition of
fluoride in the bone. The minimum  dose required  for production of skeletal fluorosis in its various
degrees is not known exactly.  However,  various studies of population groups indicate  that at
levels below 4 mglday  there is no hazard of a significant degree of accumulation,  while 6-
20 mglday causes  skeletal  fluorosis to some degree and the severe form, crippling skeletal
fluorosis, requires  a daily dose of 20-80 mg (25, 30, 2). Fluoride has been used in the past in the
treatrnent of osteoporosis,  however, clinical trials indicate that the effectiveness of this
Reports of the Scientific  Committee  for Food (43rd  series)treatment is questionable. Population sfudies on bone fracture rate in relation to fluoride in
drinking water have also yielded inconclusive results (29).
Many mutagenicity  studies are available, mostly carried out with NaF (29). It has been found
negative in bacterial systems, and positive in cultured mammalian cells (at gene and chromosome
level) only at cytotoxic  concentrations,  probably by an indirect rnechanism.  So far, no adequate  in
vivo data are available.
According  to IARC (15) the limited animal data avallable  were evaluated  as inadequate.  More
recent NTP studies performed in rats and mice have shown an increased  incidence of
osteosarcornas only in male rats. This effect was evaluated  by NTP as equivocal evidence (21,
2e).
Numerous  epidemiological  studies have been carried out to investigate  whether  there is a relation
between the occurrence of cancer and the exposure to fluoride via drinking water. IARC
concluded that the studies provide inadequate  evidence for carcinogenicity  in humans  (15, 16).
More recent studies also have not supplied evidence  that there is a relation between fluoride in
drinking  water and cancer mortality (25,2).
Conclusion
On the basis of the data reviewed above, especially as concerns the occurrence  of dental fluorosis
at concentrations  above 0.7 mgll (warm climates) and 1.5 mgll (temperate  climates), the
Committee  has no reason to deviate from the level of |.5 mgl, as given in the proposed
amendment (3) to the existing drinking water directive,  and concludes  that this level should also
apply to natural mineral waters.
4. Boron (B)
Evaluation
There are conflicting views about the essentiality of boron for man. In its report on nutrient  and
energy intakes,  the SCF concluded  that the evidence  supporting the essentiality of boron has yet
to be substantiated (27).
Boron undergoes little, if any, metabolism in the organism.  It is excreted through the kidneys with
a half-life of approximately 24 hours or less (18, 17,26) and elimination  is similar in rats and in
man (19). There is no information available on elimination  in pregnant  women or in people with
impaired  kidney function.
The most important  toxic effects of boron are on the reproductive  system. In male laboratory
animals testicular lesions have been observed in rats, mice and dogs given boron in the diet or in
drinking water (21).
of the Scientific  Committee  for Food (43rd  series)A survey of reproductive  perforunance was carried  out in 542 male workers in a borax mine using
a questionnaire  approach to test any anti-fertility effect of inhalation of borax. The mean exposure
over one year in the highest exposure  group was estimated on the basis of a mean male body
weight of 70 kg, to be 0.34 mg of boronlkg b.w./day, and no adverse effect on reproduction was
found by this indirect method (35).
Developmental  effects have been seen in rats, mice and rabbits. The critical effect was a
decreased  average fetal weight per litter in the rat. Offspring  body weight was decreased at 13.3
mg of boron/kg b.w./day and the NOAEL was 9.6 mg of boronlkg b.w./day (12,24).
No adequate study on boron is available on the developmental effects in man nor is any human
study available  of effects of boron during pregnancy  nor in persons with decreased  function of the
major excretory  organ for boron, the kidney. The Committee,  therefore,  found no basis for
deviating from the usual safety factor to be applied to the NOAEL in the most sensitive animal
species.
The Committee  noted that the two recent evaluations  of boron (8, 10) had arrived at the same no-
effect level from the animal studies but had differed in the rationale for the derivation of a safetv
factor.
Conclusion
A NOAEL of 9.6 mdkg b.w./day was established on the basis of the rat study (decreased average
fetal weight per litter). Application of the usual safety factor of 100 gives a TDI of 0.1 mg
boronlkg b.w.iday. Consumption  of 2 litres of natural mineral water/person/day  and an allocation
of 10 % of the TDI to this source of exposure would lead to a guideline value of 0.3 mg/1.
5. Manganese (Mn)
Evaluation
Manganese has been shown to be an essential element for animals.  Therefore, it is presumed that
manganese is also beneficial  or essential to humans.  On the other hand, higher doses can cause
adverse effects, especially on the central nervous system. In humans,  neurological  effects have
been observed in workers following  chronic inhalation  exposure to manganese dust and fumes.
There is, however,  only limited evidence that oral exposure might be of concern.
In vitro mutagenicity studies, including  tests on bacteria and mammalian cells, have shown that
manganese  has a genotoxic potential in the absence of metabolic activation.  So far, results of ln
vivo assays have been negative  (1). Carcinogenicity studies in rats and mice revealed only
equivocal  evidence of increased  tumour incidence  (13, l4).
of the Scientific  Committee  for Food (43rd  series)The data on the dose-relationship of changes in the central nervous  and reproductive system are
insufficient and do not allow no-effect levels to be established.  The lowest effective  doses were
seen in semi-chronic  oral studies with MnClr, in which the motor activity of male rats was
changed significantly at about 10 mg Mnlkg b.w./day (4) and testicular changes (20) as well as
muscular  weakness, rigidity of the lower limbs and marked  neuronal  degeneration in the region of
substantia nigra (11) were noticed in male monkeys  at 6.9 mg Mnlkg b.w./day.
Conclusion
From the lowest effective doses observed,  the semi-chronic oral studies,  a no-effect  level of 1
mg/lcg b.w./day can be estimated. Application of a safety factor of 100 would result in a tolerable
daily intake which would be lower than the essential intake from a nutritional point of view.
Therefore, an acceptable  maximum  level for natural mineral waters was based on the safe and
adequate  range of 1-10 mg Mniday derived  by the SCF in setting nutrient intakes (27). Taking the
upper value of this range into account and assuming an allocation  factor of 10 o/o fot natural
mineral waters and a daily consumption of 2 litres, an upper level of 0.5 mg Mn/l in natural
mineral waters appears to be acceptable.
Assumptions  concerning  consumption of natural mineral waters
The Committee stresses that its evaluations  have explicitly  assumed that the conventional
consumption value of 2 I per person per day as used by the EU and WHO for risk assessment  of
drinking water, also applied to natural mineral waters. The Committee  considered  this to be a
conservative  approach but one which allows a certain flexibility for risk management purposes.
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10 Reports of the Scientific  Committee  for Food (43rd  series)OPINION  ON STARCH ALUMINIUM OCTENYL SUCCINATE  (SAOS)
(expressed  on 2l March 1997)
Terrns of referenee
To evaluate the safety in use of starch aluminium  octenyl succinate (SAOS) as a powdering agent
when processing micro-encapsulated  vitamins and carotenoids.
Background
The related compound  starch sodium  octenyl succinate (SSOS) was accepted for general food use
as a food additive by the SCF (l). The Committee's  current evaluation of SAOS considers  the
aspect of exposure to aluminium arising from the requested use of this substance.
Technological  function
Since SAOS, unlike most other starches, has hydrophobic properties, it is used in micro-
encapsulated vitamins and carotenoids  to prevent  sticking when drying at low temperature  thereby
preventing  their decomposition.
Exposure
On the basis of the information provided by the petitioner,  the Committee made the following
evaluation which is based on a 25 o/o incorporation  rate for SAOS in the micro-encapsulated
formulations and an aluminium content of 1,25 pdmg SAOS.
Micro-encapsulated vitamin A and vitamin D
Reference values for nutrition labelling  of vitamin A and vitamin D are 500 pg (1 550 IU) and 5
pg (200 IU) respectively  (2). The potency of coated vitamin A is 325 000 IUig while that of
vitamin D is l00 000 IU/g.
The maximum daily doses of micro-encapsulated  vitamin A and vitamin D proposed  by
manufacturers  are 10 mg and,2 mg respectively, which, at a level of incorporation of 25 Yo would
contain  2.5 and 0.5 mg SAOS respectively or a total of 3 mg SAOS from both. On the basis of an
aluminium content of 1.25 pglmg SAOS, the maximum daily intake of aluminium from this
source is thus estimated to be around 3.75 pg.
Reports of the Scientific  Committee f@Micro-encapsulated  carotenoids
Carotenoids  are nonnally  added at 30 mgkg as food colours but because the colour potency of
micro-encapsulated  carotenoids is only I o/o of that of non-micro-encapsulated carotenoids, the
micro-encapsulated form of carotenoids may require addition at 3 glkg of food. At a 25 %
incorporation rate, this would be equivalent to 0.75 g SAOS per kg of food or, on the basis of an
aluminium content of 1.25 mg/g SAOS, approximately I mg of aluminium per kg of food.
Although no data are available on the foods to which micro-encapsulated carotenoids may be
added and therefore on the intake of such foods, taking account of the typical maximum daily
intake of food from all sources  (1.5 kg per day for a 60 kg adult), the intake of aluminium
resulting from the use of SAOS can be expected to be far below the average dietary intake of
aluminium which is of the order of a few milligrams  per day.
Toxicology
No toxicological data are available for SAOS but these are available for the related compound
SSOS (2). These data are satisfactory and acceptable  for the evaluation of SAOS. apart from
consideration of the aluminium content. The intake of aluminium from this source would be
considerably  below the PTWI of 7 mglkg b.w. for aluminium  established by the SCF (3).
Conclusion
Taking into consideration  the small contribution  of SAOS to the daily intake of aluminium,  the
use of SAOS  as a component  of micro-encapsulated  vitamins and carotenoids  may be regarded as
acceptable.
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Reports of the Scientific  Committee  for Food (43rd  series)OPINION  ON THE ADDITIONAL  INFORMATIOI\ FROM THE AUSTRIAN
AUTHORITIES COI\CERI\ING THE MARKETTNG  OF CIBA.GEIGY MAIZE
(expressed on 21 March 1997)
Terms of reference
The provisions of Directive 90l220lEEC have led the Commission to seek advice on the
additional  information from the three Scientific Committees that expressed  opinions  on Ciba-
Geigy maize in December  1996 and in particular,
a) does the information  submitted  by Austria constitute  new relevant scientific  evidence which
was not taken into account by the Committee at the time its opinion was delivered?
'  and, if so,
b) would this information  thus cause the Committees  to consider that this product constitutes  a
risk to human health or the environment?
The evaluation  of the SCF was limited to consideration  of risks to human health.
Evaluation of the additional Austrian  information
The Austrian point of view is described most precisely in the introduction to the additional
information  where it is stated that 'especially new scientific results  have questioned  the present
scientific possibility of a conclusive evaluation of the mechanism  of gene transfer as well as the
development  of resistance to the B.t. toxin. Accordingly,  possible risks are very hard to assess  and
should be avoided at the present state of scientific discussion'.
The new data quoted with regard to B.t. toxin relate to potential environmental risks and were not
therefore considered by the SCF. With regard to the aspects considered by the Austrian authorities
in the section 'Assessment  of the B-lactamase resistance',  the Committee has carefully  examined
the scientific argument presented  therein.
During its evaluation of CG-maize, the Committee  was aware of, and took into account, the
available scientific  knowledge concerning the unexpectedly long survival of DNA in the
environment  and the persistence of fragments  of DNA in the human body following the
consumption  of food. The likelihood of a possible gene transfer to micro-organisms  in the
intestinal  tract under specific conditions was also known and taken into consideration.  The
potential hazard arising frorn the original transformation of maize by the use of the pUC plasmid
harbouring the gene encoding  B-lactamase was given particular attention and was even the major
topic of the ad hoc expert meeting  organised jointly by the SCF and the Scientific  Committee for
Animal Nutrition (SCAN) on 6 December 1996.
Reports of the Scientilic  Committee  for Food (43rd series)In its opinion expressed on 13 December 1996, the Committee made reference to the widespread
presence in the intestine and in the environment of bacteria that harbour the naturally occurring
genes encoding B-lactam resistance and concluded  that the possibility  that the product would  add
significantly  to the already  widespread  occurrence  of ampicillin resistant bacteria in animals and
man is remote.
The Committee notes that none of its conclusions concerning the toxicology, nutritional value,
allergenicity and secondary changes  are affected by the Austrian arguments,
Conclusions
The information  submitted  by the Austrian  authorities supports the conclusion of the SCF stating
that 'the Committee  was conscious of the general question of the use of genes coding for
antibiotic resistance in marker  gene constructs  in the development  of novel foods and proposes to
scrutinise the future needs and application of marker genes'. In the view of the Committee, the
Austrian information does not provide  new scientific evidence  regarding the food use of Ciba-
Geigy maize which was not taken into account by the Committee  at the time its opinion was
delivered. Thus, the Austrian information  does not cause the SCF to consider that the Ciba-Geigy
maize constitutes  a risk to human health.
of the Scientific  Committee  for Food (43rd  series)OPTNION ON ACTTLTGHT  - A FRUCTO-OLTGOSACCHARTDE (FOS)
(expressed on 21 March 1997)
Terms of Reference
To give an opinion on the safety of Actilight  (FOS) in accordance with its proposed use as a food
ingredient.
Background
The Commission was asked by the petitioner to evaluate Actilight in the context of food additive
use in 1988. The Committee concluded at its 83rd Meeting (10 April 1992) as follows: 'The
Committee endorsed the conclusions of the Additives Working Group. Although the Committee
had no concern about exposure (estimated  at around 2 glday) through the consumption of normal
items of the diet in which fructo-oligosaccharides occur naturally, it noted that even from single,
typical portion sizes of foods to which Actilight had been added,  intakes approached  those at
which gastrointestinal  effects in humans had been reported.  Furthermore, in feeding studies with
experimental animals nurnerous effects had been seen, in some cases at all dose levels. The
Committee concluded  that for these reasons, "Actilight"  could not be considered  acceptable  for
addition to food at the levels requested'.
The petitioner responded in February 1995 by providing additional information  which it believes
addresses the concerns expressed  by the Committee. The legal status of Actilight  was clarified  by
the Standing Committee  on Food who indicated in June 1995 that it would classiff fructo-
oligosaccharide  as a food ingredient (and not as a novel food ingredient nor as an additive). At its
l00th meeting (7-8 March 1996), it was therefore  decided to examine the above-mentioned
additional information  and more recent publications  on digestion, excretion and energy value of
FOS in healthy  humans, and on the effects of chronic consumption of FOS by healthy subjects, in
the light of the previous  reservations  of the Committee related specifically to digestibility.
A complementary file provided by the petitioner presented  a more comprehensive analysis of
toxicological  studies previously  submitted.  In addition, the petitioner presented new data on sub-
chronic toxicity (90-day oral rat study), embryotoxicity  in the rat, and a study on colon
carcinogenesis after treatment with FOS and a chemical inducer of carcinogenesis.  This
information  showed that FOS has no significant  effects, other than gastrointestinal symptoms, at
doses from 5 to 40 times higher than the no-effect level for laxative effects in humans.
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Actilight fiucto-oligosaccharides  (FOS) result from the action on sucroso of a fructosyl
furanosidase  present rn Aspergillus niger. Sucrose plays the dual role of fructose donor and
fructose  acceptor. The first reaction  on two sucrose  molecules  results in kestose (glucose-fiuctose-
fructose, GF2). The same enzyme acts on kestose to produce nystose (GF3) and on nystose to
produce fructosyl-nystose  (GF4). Bonds between fructose units are b (l-2) (l).
There is no enzyme present in the small intestine that can specifically hydrolyse the (2-I)-b-
glycosic linkages  found in FOS. Consequently,  FOS are not hydrolysed nor absorbed in the small
intestine but are totally fermented  in the colon. Their main nutritional  properties  and their value in
human nutrition are related to their inability  to be hydrolysed in the small intestine and to their
capacity to reach the colon and to be fermented  by the microflora (l).
Studies in rats showed that FOS are not hydrolysed by salivary and pancreatic  amylases, and that
few or none are hydrolysed by intestinal brush border enzymes (2). Moreover, FOS recovery from
rat small intestine  was approximately the same as that of an unabsorbable  marker (3). Long-term
ingestion  of FOS did not cause induction or suppression of the rat intestinal brush border  enzymes
(2). FOS did not influence the transmural potential difference of everted  sacs prepared  from rat
jejunum (4). In addition, when injected intravenously to rats, FOS are rapidly excreted  in urine
without having undergone  any degradation,  suggesting that FOS are not used as an energy source
in the body (2). On the other hand , in vttro incubation of 1U-14C) FOS with the caecal content of
rats showed that most of the label appeared  in short-chain  fatty acids (SCFAs). FOS fed to normal
rats showed rapid fermentation,  whereas germ-free  animals delayed excretion of the label for
many hours with substantial  amounts  appearing  in faeces (5). Compared  with other undigestible
sugars (e.g. cellulose, pectins  or lactulose),  the fermentation of FOS produced  higher percentages
of propionic  and butync acid, which may be relevant to predicting their metabolic effects
in vivo ($).
In hurnans, no change in blood glucose was noted after oral ingestion  of FOS (7). Breath-
hydrogen  studies have also shown that FOS are fermentable,  resulting in an amount  of hydrogen
in breath similar to that excreted  after ingestion of an identical  load of lactulose (8), suggesting
again that FOS are not digested  in the human small intestine. This was recently confirmed by in
vitro and in vivo studies (9). Only sucrose was hydrolysed during in vitro incubations  with
homogenates  from duodenal  mucosa, whereas the constituent oligosaccharides  of FOS were not
hydrolysed at all. In vivo, the fate of FOS in the human gastrointestinal tract was evaluated in six
healthy volunteers  over an 1 l-day period. After an equilibration  phase ,20.I g FOS/d was given in
three identical postprandial doses:  distal ileal output of FOS and its constituent components  were
determined  by intestinal aspiration after a single meal, and the amounts of FOS excreted in stools
and urine were also measured.  Most of the ingested FOS, 89 + 8.3 oh (^ + SEM), was not
absorbed in the small intestine,  and none was excreted in stools, indicating that the portion
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FOS (0.12 + 0.04 %) was recovered  in urine.
kJ, i.e. 2.4kcaUg(9).
by colonic flora. A srnall fraction of the ingested
The mean estimated  energy  value of FOS was 9.5
Digestive tolerance
The digestive  tolerance to undigestible sugars depends on the amount  ingested, on the presence of
factors that reduce their osmotic load in the small intestine, and on the degree of adaptation  of the
colonic microflora to ferment these sugars. The importance of the osmotic effect of undigestible
sugars is determined  by the concentration of sugar leaving the stomach. This obviously  depends
on the amount of undigestible sugar ingested  but also on factors reputed to slow down gastric
emptying, such as the energy content  of the meal, the solid content,  and the viscosity.  The worst
conditions for testing  the digestive tolerance to undigestible sugars are encountered  after fasting,
when sugars  are tested in a single liquid load, and when the microflora of the subject has not been
adapted  by chronic sugar ingestion. All these factors must therefore be taken into account  when
comparing  digestive  tolerance thresholds  of different undigestible sugars  (1).
Animal studies
The influence of chronic intake of FOS on growth and intestinal function  was investigated in rats
by Tokunaga  et al. (10). Male Wistar rats, initially weighing  40-50 g each, were fed ad libltum
for 6-8 weeks. The only variable in the experimental diets was the carbohydrate source (corn
starch only, corn starch partially replaced by 10 or 20 % FOS, or by 20% glucomannan), daily
food intake was similar in all four groups of six rats each. After feeding rats on these diets for six
weeks, the body weight gain of the group receiving  the 20 % FOS diet was significantly lower
compared  with the control group. In animals on the l0 o/o diet, no significant decrease in body
weight gain was observed. A remarkable suppression  of body weight gain was also observed  in
animals consuming the 20 Yo glucomannan diet (a kind of dietary fibre). The smaller  body weight
gain was interpreted  as a consequence  of an incomplete  utilisation  of FOS as an energy source,
The feeding of 10 o/o and20% FOS diets produced a significant  increase in both wet weight  and
the ratio of caecum to colon weights: a greater effect was observed in the caecum that in the colon
of animals  fed on the 20 % FOS diet, as in the case of animals fed on 20 % glucomannan  diet. A
similar enlargment of the caecum and colon has been observed in rats fed with dietary fibres such
as pectin,  cellulose,  guar gum and wheat bran.
The faecal wet weight increased significantly in animals fed on either the 10 o/o or the 20 % FOS
diet (p < 0.01), although the range was considerable.  The gastrointestinal transit time was about
28 h,2I h and l4 h in the control , l0 oh and 20 % FOS diets respectively, in inverse correlation to
the faecal wet weight. The concentration of volatile acids (SCFAs) per gram of wet faeces also
greatly increased in animals fed FOS or glucomannan compared  with the control group, but the
profile of SCITAs was different, indicating that the effects on intestinal microflora  also differ.
18 Reports of the Scientific  Committee  for Food (43rd series)Finally, it was pointed out by the authors that rats developed  diarrhoea  after starting  FOS feeding.
This stopped within 2 to 3 weeks, differing with individual rats. However, FOS intake of rats in
the present study was more: 10 g per kg b.w. in the early period of feeding.  Another study, quoted
by Tokunaga et al., but published  only as an abstract, has shown previously that single-dose
intake of FOS at less than 0.8 g per kg b.w. does not produce  diarrhoea  in males, but that it does
at above this level, and that females are more resistant to diarrhoea than males (10).
Human studies
The gastrointestinal  tolerance of the mixture of oligosaccharides,  consisting  of glucose linked to a
series of 2, 3 or 4 fructose molecules,  was evaluated in three studies.
The Japanese  study
A first estimation of the maximum non-effective dose of FOS in humans and of the 50 0/o laxative
effective dose (the amount of FOS which causes diarrhoea  in 50 Yo of people, EDr) was
performed in 85 healthy Japanese volunteers (51 men, 34 women) by Hata and Nakajina (11)' To
test the effect on the digestive tract using diarrhoea as index, a FOS mixture (56 % FOS, 12 
o/o
sucrose, 29% glucose,3  % fructose) given in six different dosages (0.21, 0.27,0.40,0.53,0.67
and 0.8g/kg b,w.) in 180 ml of water after lunch was compared  with a sucrose mixture (68%
sucrose, 29 o/o glucose,3 o/o fructose). At the administration of 0.2 to 0.3 g/kg b.w. standard dose,
diarrhoea did not occur in both men and women. The maximum  non-effective  dose of FOS on
diarrhoea (expressed  as pure FOS) was 0.3 gkg (approximately  44 g of the FOS mixture) for
men, and O.aglkg (approximately  49 g of the FOS mixture) for women. In comparison, the
maximum non-effective  dose of sorbitol for men was 0.15 girg.The EDso of FOS was 0.78 g/kg
for men and 0.84 gikg for women  (EDro for sorbitol: 0.5 g/kg). Incidence of diarrhoea due to
doses above the maximum non-effective dose was higher in men than in women  by approximately
rc %, Effects of 0.27 g FOS/kg b.w. on the abdominal syrnptoms  and the macroscopic  aspects of
stools were not influenced by differences in the form of intake (FOS mixture us purified FOS,
with or without mixing with food), sex or age. At the same dosage (la g/d for women and 17 g/d
for men), no significant  difference  was noted between FOS and sucrose  (11)'
The US study
Clinical tolerance  to regular consumption of FOS was also studied by Stone-Dorshow  and Levitt
(8). In volunteers receiving  a constant  daily amount of FOS (5 g three times a day with meals),
they showed that gaseous  symptoms,  such as flatulence, bloating and abdominal  discomfort  were
significantly  rnore severe in subjects ingesting the FOS than in control subjects ingesting sucroso.
Moreover, symptoms  did not improve after a l2-day period on FOS. However, at this daily dose,
with the exception  of flatulence, symptoms  were rated absent or mild and no subject experienced
diarrhoea.
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The French study, performed  on healthy  volunteers (6 females, 8 males, aged from 2l to 37
years), was a double-blind,  randomised cross-over study. The tolerance to FOS was compared
with that to sucrose. Both sugars as hard candies (2.5 g of sugar each) were consumed
occasionally and regularly. In the first period, FOS consumption was occasional,  i.e. one dose of
FOS and sucrose  were tested at random  on Tuesdays and Thursdays  of each week. To avoid any
adaptation,  subsequent  ingestions  of FOS thus were separated  by at least 5 days. The starting dose
was 10 g. Sugar doses were increased by l0 g until diarrhoea  and/or a symptom graded  3
occurred, or when volunteers  did not want to ingest more candies.
In the second period, volunteers  were asked to consume the same sugar (either FOS or sucrose)
every day according  to an increasing schedule lasting at most 18 days. In the same manner,  they
consumed the other sugar after a washout  period of 15 days. According  to the schedule, subjects
should  reach the threshold found in the first period (diarrhoea and or grade 3 symptom) on the
15th day. On days 16, 17 and 18 they should ingest this dose plus 10, 20 and 30 g, respectively.
As in the first period, subjects were asked to stop sugar ingestion if diarrhoea and/or a grade  3
symptom  occurred.
At each dose, tlte mean scores for each symptom (flatus, borborygmi, bloating, cramps, diarrhoea)
experienced with FOS and sucrose  were compared and the 50 a/o effective  dose (ED5s) was
determined  graphically. H, excretion in breath was measured on the 15th day of FOS and sucrose
consumption. Iiifteen days after the conclusion  of the study, breath H, excretion was again
assessed  before and after FOS ingestion,  to evaluate if H, excretion  was higher in these conditions
than H, excretion  measured  for the same daily dose during chronic consumption  of FOS.
Symptomatic responses and laxative thresholds were roughly similar during the occasional and
regular  consumption  of FOS. The threshold  FOS dose was reached in all subjects:  13 experienced
diarrhoea and one severe abdominal pain in the first period. During the second one, t  had
diarrhoea, I complained  of severe flatus and 4 did not want to take more candies. In both studies,
approximately  l0 o/o of the volunteers complained of flatus and borborygmi with 10 g/d. For
excess flatus, the first dose at which the severity of the symptorn was significantly higher with
FOS than with sucrose  was 30 g; for borborygmi,  bloating  and abdominal cramps,  this dose was
40 g; the mean threshold and laxative doses were approximately  50-60 g, as ED56 for diarrhoea.
The mean volume H, excreted in breath was not significantly  higher during the occasional
consumption  of FOS than during chronic consumption (183 + 103 vr I20 + I04 mllI6
h, p : 0,16). H, excretion  was 45 + 18 mll16 h during the sucrose  consumption.
The authors concluded that chronic consumption of FOS initiated cautiously  with subsequent
gradual  increase  did not improve tolerance, nor reduce excretion of hydrogen.  Their results
confirm that adaptive response of the microbial flora may be different with various unabsorbable
sugars (12, I3).
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Metabolic  studies on Actilight  (a mixture of oligosaccharides  consisting of glucose  linked to 2, 3
or 4 fructose units) have shown that FOS are poorly absorbed in the human small intestine, but
completely fermented by colonic flora.
Diarrhoea has been reported  in rats fed a 10 o/o or 20 % FOS diet (more than 10 gikg b.w. in the
early period of feeding) but the laxative effect of FOS stopped within 2-3 weeks. However, the
faecal wet weight and the concentration  of SCFAs  per gram of wet faeces remained higher than in
control rats at the beginning of the sixth week of l0 or 20 % FOS diet. Gastrointestinal transit
time was inversely correlated with the faecal wet weight. In animals on the 10 % FOS diet, no
significant decrease in body weight gain was observed. The body weight gain of the group
receiving the 20 % FOS diet was significantly  lower, compared with the control group.
In humans, the maximum  non-effective  dose of FOS (expressed as pure FOS) on diarrhoea  was
0.3 g,kg b.w. (approximately  24glday) for men and 0.4glkg b.w. (approximately  28 g/day) for
women. At the administration  of 0.24.3 g/kg b.w., diarrhoea did not occur in either men or
women.
With 15 g (5 g three times a day with meals)  gaseous  symptoms,  such as flatulence, bloating  and
abdorninal  discomfort were significantly  more severe in subjects ingesting the FOS than in
control subjects ingesting sucrose. At this daily dose, with the exception of flatulence, symptoms
were rated absent or mild and no subject experienced diarrhoea.
The amount of FOS which causes diarrhoea in 50 %o of healthy adult volunteers (ED.) was
estimated  in  two different studies as 0.8 glkg b.w., i.e. approximately 50-60 glday'
Gastrointestinal  symptoms  did not improve after a 12 to 15 day period on FOS. In comparison  the
maximum  non-effective  dose of sorbitol and EDro for sorbitol were lower (0.15 g/kg b.w. and
0.5 g,ikg, respectively) than those for FOS.
In accordance with its previous opinion  on polyols (16th Series), the Committee concluded  that,
although laxation  may be observed  at high intakes (more than 30 glday) a consumption of the
order of 20 g a day of FOS is unlikely to cause more undesirable  laxative symptoms  than isomalt,
lactitol, maltitol, mannitol, sorbitol and xylitol. The Committee has no objection  to the use of
Actilight provided the limitations  due to its laxative action are kept in mind.
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Reports of the Scientific  Committee  for Food (43rd series)OPINION  ON DIACETYLTARTARIC  ACID ESTERS OF
MONO- AND DIGLYCERIDES (DATEM E-472e)
(expressed  on 13 June 1997)
Terms of Reference
To re-evaluate the use of DATEM (F472e) for general food uses and to consider the use of
DATEM  (E-472e) in foods for special medical pu{poses (FSMPs) for infants and young children
based on protein  hydrolysates and amino-acids, and in infant formulae  and follow-on formulae
based on parlial protein hydrolysates  and amino acids for infants in good health.
Background
An application  was received in 1992 for the use of E-472e as an emulsifier in mother's  milk
substitute  preparations  suitable for infants allergic to cow's milk and/or soya protein and also in
FSMPs in children suffering from various metabolic disorders.  The Committee has been informed
that$-472e  is the only technologically  useful emulsifier  in preparations  which do not contain any
protein. Clinical information  additional to the other data already  available in 1974 has now been
submitted  to the Committee.
This emulsifier was also evaluated by JECFA in 1966 and 1974 (1). In 1966 JECFA established
for E-472e  an ADI with an unconditional  zone of acceptance of 0-25 mglkg b.w. and a
conditional  zone of acceptance of 25-50 mgkg b.w. separately  from the ADI for other tattatic
esters of mono- and diglycerides because diacetyltartaric  acid does not occur in nature. ln 1974
JECFA confirmed an ADI of 0-50 mdkg b.w. for E-472e on the basis of then available data (2)'
In 1978 the SCF reviewed these data and confirmed  an ADI of 0-50 mglkg b.w. in its first report
on emulsifiers (3).
The SCF agreed  at its 107th Meeting (13 June 1997) to the temporary  use of E472efot  two years
in FSMPs for infants and young children at levels up to 0.3 gll (as reconstituted  from dry
powders),  up to 0.4 gll (liquids) and up to 5 g/kg in gluten-free  bakery products  for gluten
sensitive patients (4).
Specification
The recent submission  contains only the JECFA specification of 1978 (5) for E-472e and quotes a
saponification value of 490-520, an acid value of 80-100 and an iodine value of approximately
40. There exists a new JECFA specification of 1995 (6) which is, however, not mentioned in the
new submission.
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When the Committee first assessed the safety to health of E-472e it considered  only its use as an
emulsifier  in food generally. A re-evaluation of the available safety data has become  necessary,
because  requests have now been received for the additional use of E-412e in FSMPs for infants
and young children and in infant formulae and follow-on formulae for children in good health.
Biological data
No biological  data additional to those evaluated by the Committee in its first report on emulsifiers
(3) have currently been submitted  to the Committee for evaluation except for some recent clinical
studies with a mother's milk substitute  containing  E-472e. The Committee is also aware that a
long-term study has recently been completed.  The original  biological data included a metabolism
study in rats fed E-472e labelled with '"C in the 2 carboxyl groups to determine  absorption,
distnbution and excretion through the lungs and in the urine (8). A Z2-month feeding study in
dogs was used to determine  digestibility and the body distribution  of the tartaric acid moiety (8).
In vitro studies demonstrated  hydrolysis of E-412e in aqueous  media into mono- and
di-glycerides, acetylated  tartaric acid, acetic acid and turtaric acid, particularly  in the presence of
pancreatic enzymes (9).
The toxicological data examined in the earlier review included acute toxicity studies in rats,
rabbits  and dogs. These showed absence of any significant  acute toxic effects (8). A 30-day study
in dogs given E-472e i.v. and a feeding  study in dogs extending over 25/z months,  also showed no
adverse  effects even at ihe 20 o/o dose level in the feed (10). In a two-year feeding study in rats, no
adverse effects attributable to E-412e even at 20 o/o incorporation  in the diet, the highest dose
level tested, were noted (8). Furthefinore, a reproduction study in rats extending  over 22 months
also showed no adverse findings related to the feeding  of E-472e up to a dose level of 20 o/o tnthe
diet (8). F-472e was found to be non-mutagenic in in vitro assays using Salmonella typhimurium
and Saccharomyces c ereviseae (l 4).
Human clinical data
Several recent tolerance trials with a mother's milk substitute preparation  containingZ 000 mg/kg
E-472e were carried out in new-born infants  at high risk for atopy and in infants and children
known to suffer from allergy to cow's milk. The parameters examined included  weight gain,
growth, titre of IgE specific for cow's milk, incidence of positive skin prick tests for allergy to
cow's milk and incidence  of allergy to cow's milk. In none of these prospective studies were any
adverse effects noted in the parameters examined  other than those due to the existing underlying
allergy or atopic predisposition (11,12,l3).
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Given the requested levels of use of E-472e in foods for infants and their low body weights, it is
relevant to compare the predicted intakes with the ADI for E472e of 50 mg/kg b.w. and the
possible formation of one of its hydrolysis products, tartaric acid, with the ADI for that substance
of 30 mglkg b.w.
The requested levels of use of E-472e in formulae and follow-on formulae based on hydrolysed
proteins for infants in good health and for use in FSMPs vary considerably.  One group of
products  requires  levels up to 0.175 g/100 g of dry product, while others require 1.21 gll00 g of
dry product (15). Intake data have been provided for three typical  products  in the lower use range
of E-472e and these all give estimated intakes of E-472e which are at or below an ADI of
50 mg/kg b.w. (16). Intake data have also been provided for a tlpical product in the upper use
range of E-472e, containing 1.6 9/100 g of dry product.  These intake data range from 194-274
mg/kg b.w.iday for infants between  0 and 12 months of age (15), implying they would regularly
exceed the ADL
Considering tartaric acid, the Committee has been informed  that the E-472e preparations
requested for use in formulae and follow-on formulae based on hydrolysed proteins for infants in
good health and for use in FSMPs would conform to Food Chernical Codex limits, i.e., would
contain up to 20o/otartaric  acid (15). Thus any intake of more than 150mdkg b.w./day of this
type of E-472e preparation could exceed the ADI for tartaric acid. This suggests that use of E-
472e at the requested higher  use range of 1.2-3 9/100 g of dry product  would result in the ADI for
tartaric acid being regularly exceeded. (It should also be noted that the EU specification  for E-
472e allows preparations  containing up to 40 o/o tartaric acid to be used in the European
Community).
Conclusions
The Committee has reviewed  the total information on E-472e currently available to it and has
noted that a new specification  for E-472e, aligned with the one of 1995 has not been supplied.
The biological data show that hydrolysis  in the mammalian gut is sufficiently slow to allow the
absorption of some unhydrolysed E-412e. The identity of the urinary metabolite remains
undetermined.  The compound has no acute toxicity by the oral route. The available short-term,
long-term and reproduction  studies, though inadequate by present-day standards, provide
collateral  evidence for the absence of serious  adverse effects, when E-472e is ingested  in high
doses. Genotoxicity has not been adequately studied as neither in vitro nor in vivo tests for
chromosomal  aberrations  have been provided. However, the clinical studies with a mother's milk
substitute containing  E-472e demonstrate  that E-472e is well tolerated by infants and children
suffering from allergy to cow's milk.
z5 Reports of the Scientific  Committee  for Food (43rd  series)In these circumstances  the Committee is prepared  at present to set a temporary ADI of 25 mgkg
b.w. for general food uses which represents half the ADI established  in 1978, but wishes to see
the full presentation of the recently completed long-term feeding study in laboratory animals
within three months. In the absence of these data the Committee may have to consider further
restrictions  on the use of E-472e.
The Committee is unable to express a view on whether E472e  is acceptable for use in formulae
and in follow-on  formulae  based on hydrolysed proteins for infants in good health and in the
meantime considers  that it should not be used in such products. As mentioned previously, the
Committee  has already agreed to the temporary  use of E-472e for two years in FSMPs.
The Commiuee will reconsider  the request for use in infant formulae and in follow-on formulae
based on hydrolysed  proteins  for infants in good health, its recent temporary acceptance for use in
FSMPs and the temporary ADI now set for general  food use once the following information is
supplied,  or within two years of publication of this opinion, whichever is the earlier:
i.  an adequate  specification which also includes  a limitation for tartaric acid to 20 yo,
ii.  fulI submission of the recently completed  long-term study in laboratory animals,
iii.  studies  on reproduction and teratology conducted to modern  standards,
iv.  a test fi>r chromosomal  aberrations in mammalian cells in vitro.
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(expressed on 13 June 1997)
Terms of Reference
To re-evaluate the safety in use of canthaxanthin as a food additive in the light of additional
information received.
Background
Canthaxanthin was considered by the Committee  for the first time during its comprehensive
review of the colouring  matters in food in 1983 (l), when the Committee established  an ADI of
015 mglkg b.w./day. Subsequently new data, derived from studies on individuals  taking
canthaxanthin for therapeutic, dermatological  or cosmetic purposes (e.9. as sun-tan producing
agent),  showed  that the high doses employed for these purposes  could induce the formation of
crystalline deposits in the retina, eventually identified as canthaxanthin. These data pointed to a
lowest effect level in man of 30 mg/day (0.5 mg/kg b.w./day). Consequently, in 1989, the
Committee changed the existing ADI to a temporary ADI of 0-0.05 mg/kg b.w./day, using a
safety factor of l0 because of the availability of human data (2). The Committee also requested
the provision of certain additional information during the next five years to elucidate  more
precisely the pharmacokinetics underlying  this deposition of canthaxanthin in the retina of both
animals and man and to establish whether  any functional visual effects were associated  with
these findings. Further information supplied by the manufacturer to a national advisory
committee together with their assessment of this information was later communicated to the
Committee.  Following its own assessment in 1992 of this new information, the Committee
decided to leave unchanged  the temporary ADI of 0-0.05 mdke b.w.lday (3), the validity of
which it had limited in 1990 to a period of five years. Additional  information has now been
submitted to support a reconsideration  of the Committee's 1992 assessment. The same
information was reviewed  by JECFA in 1995, which established an ADI of 0.03 mdkg b.w (a).
Information submitted since the 1989 review
Anirnal studies
Long-term  feeding studies in rats, extending over 104 weeks, were carried out recently as two
separate studies in males and females  using dose levels ranging from 5 to 250 mg/l€ b.w./day
(5). Earlier studies in the mouse  extended  over 98 weeks (6) and in the dog over 52 weeks (7).
None of these studies showed any evidence of crystal deposition in the retina of the test animals
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females with associated biochemical changes in the males and histological  changes in the liver of
males and females interpreted as evidence of a possible  hepatotoxic effect. The NOAEL  in these
rat studies was 5 mglkg b.w.lday. No specific adverse effects  were seen in the mouse apart from
pigment deposition in hepatic sinusoidal cells. No changes in tumour incidence  were noted even
at 1 000 mg/kg b.w., the highest dose level tested. The dog study showed  only that the adipose
tissue contained the highest canthaxanthin  concentration, followed by the adrenals and the liver.
A three-year  feeding  study in cynomolgus monkeys,  using doses ranging from 0.2 to I 000 mg/kg
b.w./day,  revealed no treatment-related  effects on body weight gain, food consumption,
haematology, clinical biochernical  parameters and urinalysis. The only treatment-related
macroscopic  changes  were orange-red  discolourations of the gastrointestinal mucosa, the adipose
and the connective tissues. No unusual findings were noted in organ weights and the
histopathology of all organs examined  showed no evidence of any systemic  target organ toxicity.
However,  examination of the retinae showed  birefringent  inclusions especially in the peripheral
regions. At the lowest dose of 0.2 mgkg b.w./day no inclusions were seen. Canthaxanthin
concentrations  in the retina correlated  with the presence of birefringent  inclusions. These and the
microscopic crystalline  inclusions in the liver were shown by chemical analysis  to be associated
with canthaxanthin.  No functional visual impairment  was associated with these inclusions.  The
NOAEL for systemic  toxicity was therefore I 000 mglkg b.w.lday  and for observable  inclusions
in the retina it was 0.2mgkgb.w./day (8).
Recent pharmacokinetic and metabolism studies in the cynomolgus monkey, using toc-labeiled
canthaxanthin showed plasma concentrations to be higher than those in the blood with peak
values occurring  in males within 4 hours and females  within 6 hours. Faecal excretion was the
major route of elimination amounting to 85-90 %o, winary excetion  accounted for 1.6-3.60/o,
while tissue retention ranged from L6 to 4.6 o/o and occurred  preferentially in the adrenals.
Monkeys therefore  appeared  to absorb from 3 to 8 o/o of orally administered  canthaxanthin.  (9).
In a study comparing the pharmacokinetics in rats and monkeys  under steady state conditions the
urinary excretion was faster in the rat, some 4.6% being found in the rat urine after 96 hours
compared with 2.lo/o in the monkey urine over the same period. Some 9I.4% of the
administered  dose was recovered  from the rat faeces after 96 hours compared with 87 .2 Yo after
the same period in monkey faeces. Overall  tissue residues after 96 hours amounted  in the rat to
about 0.8oA, accumulating mostly in the spleen and liver, whilst the equivalent figure for the
monkey after 96 hours was 5.1 % with accumulation being highest in the adrenals. Excretion and
metabolism were thus faster in the rat than in the monkey.  In the rat the urinary metabolites
contained some very polar compounds which were present only in trace amounts in monkeys,
while monkey urine contained some less polar compounds  absent from rat urine. In the monkey
retina 4'-OH-echinenone and isozeaxanthin were identif,red as metabolites. The urinary
metabolites have not been identified so far in both species. The mean plasma level of
canthaxanthin  in the monkey at the NOAEL of 0.2 mglkg b.w. was 156 pgll (10).
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the retina, various other species  were exposed to this colourant. Thus, the ferret was found to be
unsuitable  as no canthaxanthin  residues could be detected in any of its tissues (1 1). Five different
mouse sffains were examined but little deposition in the retina could be detected and the
distribution differed from that found in humans. However,  some functional ERG effects were
noted which were reversible (12). Birefringent crystals accumulated  in a dose-related  manner in
the retina of broiler chicken  exposed to canthaxanthin,  correlating  also with the plasma
concentrations  (13), Guinea-pigs  accumulated  the colourant in their retina after some 10 months
treatment  (14).
Canthaxanthin administered to rats at a dose of 300 mg/kg diet (15 mglkg b.w.) for 15 days
increased the concentration of hepatic &so and thereby the activities of the hepatic isoenzrymes
P4501Al  and PqsolA2.  There was co-induction of the microsomal Phase II enzyme  activities of p-
nitrophenol-  and 4-hydroxybiphenyl-UDP  glucuronyl transferases as well as quinone reductase,
an effect reminiscent of 3-methylcholanthrene  inducing activity ( 1 6).
In vitro studies
Neuronal retina reaggregate culfures, derived from chick embryos, were found to be a suitable
system to study cellular crystal deposition. Red-brown birefringent  entities formed in these cells
in proportion to the amount of canthaxanthin  in the culture medium. No accumulation occurred  at
120 ltgn medium but crystals appeared  at 1200 pgll medium (15).
Human ophthalmological data
A retrospective  biostatistical analysis of 411 cases of canthaxanthin  treatment  either for cosmetic
or therapeutic  reasons, for which sufficient  relevant information  was available, indicated that 95
individuals had a crystal retinopathy.  This finding occurred only when high doses had been
ingested over long periods and a dose-response  relationship was discernible. A dose of 30 mg (0.5
mg/kg b.w.)/day or a cumulative intake over a prolonged period of 3 g/person  appeared to be the
lowest effective dose (LEL) causing crystal deposition  in the retina. No such deposits were
reported with exposures of less than 30 mg/day. Doses above 105 mg (1.75 mglkg b.w.)/day  led
to crystal  deposition  in the retina in 50 % of cases (17).
Some reversibility  of the deposits of canthaxanthin  in the retina was noticed in patients who, over
12 years, had accumulated  these deposits  and had thereafter discontinued treatment for at least
five years (19).
No hepatotoxicity was detected in 11 patients  treated for up to 12 years for erythropoeitic
protoporphyria with cumulative doses up to 150 g (20).
An earlier review of the ocular toxicity of canthaxanthin in persons with a high intake of
canthaxanthin and deposits in their retina had demonstrated that this phenomenon was not
associated clinically with any significant adverse functional visual defects. However, a
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intensities  without any change in peak latency was detected. This small functional effect was:
not detectable by psychophysical  tests;
always associated with normal visual acuity and colour vision but occasionally with minimally
reduced threshold  static perimetry and mild reversible  delayed dark adaptation;
not due to retinopathy with loss of retinal sensitivity  because  the ERG kinetics and the ERG a
waves (parameter  for photoreceptor activity) were unaffected and weak stimuli did not induce
any ERG b waves (parameter for general retinal damage);
due to a depolarisation  of the glial Miiller cells, because crystals were found near the end feet
of the Miiller cells near the inner surface of the retina. These crystals were eventually voided
into vacuoles and either phagocytosed  by cells of the retinal pigment epithelium  or
disappeared  very slowly from the retinal surface due to the absence of an active removal
process.
These changes  were not considered  to be of pathological  significance or indicative of significant
functional damage to the retina. In this review the LEL for effects on the ERG b wave was
estimated to lie between 0.25 and 1 mglkg b.w (18).
Human intake estirnates
According  to Directive 94136/EEC the use of canthaxanthin  as a food additive is restricted  to the
colouring of saucisse de Strasbourg.  The Committee is aware that it is also used as an animal feed
additive for poultry and fish and that residues may therefore be present in egg yolks and farmed
trout and salmon. Canthaxanthin  also occurs naturally in certain wild mushrooms.  Reliable intake
estimates are not available at present but data suggest that0.2 mg/egg and 0.1 mg/100 g fish are
representative  residue levels. In view of the low ADI it is particularly  important that intakes from
all sources  should be taken into account in any future risk assessment.
Conclusion
The lowest effect level for ERG b wave changes in man was 0.25 mg/kg b.w.lday but in view of
the fact that these changes  were not of pathological significance  or indicative of significant
functional  damage to the retina, a safety factor of 10 is considered  appropriate.  This is supported
by the finding of a one order of magnitude difference between  the plasma  level (156 pgll) at the
NEL in monkeys and the in vitro concentration (1 200 pg/l medium) first showing the presence
of cellular microcrystal formation in neuronal  retina reaggregate cultures. An ADI of 0.025
mglkg b.w., rounded up to 0.03 mg/kg b.w., can therefore  be established.
Reports of the Scientific  Committee  for Food (43rd series) 31The Committee considers that up-to-date information should be obtained on human intake from
the use of canthaxanthin  in animal feeds to give assurance  that total exposure by this route would
not exceed  the ADI.
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AS A FOOD COLOUR
(expressed  on 13 June 1997)
Terms of reference
To advise on the safety in use as a food additive of a beta-carotene  preparation produced from
Dunaliella  salina.
Background
A first petition has been introduced for the addition to the list of food colours authorised  in the EU
of beta-carotene produced in a bioreactor by a unicellular alga, Dunaliella  salina.  The
Committee had given a first opinion on l0 December 1987 (21st series of reports) in which it
asked for more information  about the composition of the product and on the process used for its
preparation. In 1991, the additional information provided was not considered satisfactory  to
judge on the safety of the product and this first petition was withdrawn. In 1992, a new request
was made by another petitioner for the same 'natural beta-carotene' also produced  by Dunaliella
salina, but grown in large saline lakes located in Whyalla, South Australia. By 1997 the
information available  was considered sufficient by the Committee to give the following opinion.
Safety evaluation
Composition
The beta-carotene  preparation  is a dispersion  in a soya bean oil (containing 0.3 % natural
tocopherol) at a concentration  of 20-30 %. It is composed of all-trans- and of cis- (mainly 9- but
also 13- and 15-) isomers. The respective concentrations of trans- and cis-isomers have been
found to be in the range of 50i50 to 71129. The other major components  are alpha-carotene  and
oxygen containing carotenoids.  It also contains  minor constituents such as sterols, hydrocarbons,
free fatty acids, oxidised carotenoids  and chlorophyll.  0.5 % of the product before the addition of
soya oil remains unidentified.  The heavy  metals content  is very low (less than 10 ppm expressed
as Pb). Microbiological contamination could not be found in the samples analysed  (total count,
E. coli, yeast and mould not detected in 0. I g, Salmonella not detected in 10 g)"
Stability
The Committee  was satisfied that the beta-carotene preparation  was stable.
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Dunaliella salina grows in 30 o/o salt concentration, coupled with high light intensity and high
temperature. The Committee  was informed that beta-carotene content of the culture, pH and
brine density  are measured  on a daily basis. Weekly controls  include  chemical analysis of the
algal cells and of the brine as well as a microscopic  examination of the cells. The data provided
demonstrate  a batch-to-batch consistency.  Harvesting of the algal cells and concentration of the
beta-carotene from the cellular components  involve  only physical processes.  Isolation of the beta-
carotene is obtained after several steps: breakdown  of protein and carbohydrate into soluble
components by food-grade  enzymes; extraction of the beta-carotene using an essential oil;
saponification; partial crystallisation without isolation of carotene  crystals; and finally oil
dispersion  of the beta-carotene material and adjustment  of its concentration.
Toxicological data
Dunaliella salina belongs to the Chlorophyceae.lt  is considered that this unicellular  alga, like 25
other species of Chlorophyceae  which are classified as food sources, does not produce toxins.
Acute toxicifii:
LDro of a preparation  containing 30 % of beta-carotene is higher  than 20 g/kg b.w. in the mouse.
Short-term toxiciry:
Several  studies, lasting between  two and eight weeks,  have been conducted  on rats and chicken
with a powder of the alga Dunaliella bardawil  (which the Committee  has been informed is
identical to the species Dunal[ella salina) without signs of toxicity up to the equivalent of 0.I %
of beta-carotene in the diet.
Multigeneration  reproduction study :
No toxicity has been assigned to a powder of Dunaliella bardawil ingested by the rat up to l0 o/o
in the diet (equivalent  to 0.2% of beta-carotene).
Genotoxicity:
The algal beta-carotene  was unable to induce gene mutation or chromosomal aberrations  in two
Ames tests and one chromosome  aberration  assay in human lymphocytes.
Data obtained on the algal powder provide  reassurance  of the absence of toxicity of the
cornponents  other than beta-carotene.  This is important for the safety evaluation of the beta-
carotene  preparation  in the absence of a total crystallisation of beta-carotene.
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On the basis of the information  provided, the Committee consider  that the use of a dispersion of
beta-carotene produced by the alga Dunaliella  salina growing in large, shallow saline lakes in
Whyalla, South Australia, is acceptable as a food additive. This opinion  is expressed on the basis
of a maximum use level of this preparation  around 50 ppm (equivalent to around 10 ppm of beta-
carotene).
This conclusion is valid only for the beta-carotene  produced in the conditions  and at the sites
described in the dossier provided by the petitioner which provided reassurance on the
composition  and relative purity of the material. A specification should be developed which
complies with all the above information  and recofilmendations.
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YOUNG CHILDREN IN GOOD HEALTH AND IN FOODS FOR SPECIAL
MEDICAL  PURPOSES FOR INFANTS AND YOUNG CHILDREN
(expressed on 13 June 1997)
Terms of reference
To consider the safety-in-use of certain additives in infant formulae,  follow-on formulae and
weaning foods for infants and young children in good health and in foods for special medical
purposes (FSMP) for infants and young children.
Background
The use of additives in foods for infants and young children in good health and in FSMP for the
same age group is controlled under European  Parliament and Council Directive  95l2lEC  on food
additives other than colours and sweeteners (l). This restricts the additives permitted in infant
formulae, follow-on formulae and weaning foods for infants and young children in good health to
those listed in Parts 1-3 of Annex VI to the directive.  The use of additives in FSMP for infants
and young children is controlled under Part 4 of Annex VI of the same directive, which permits
all the additives listed in Parts l-3 to be used in FSMP, with no additional  additives currently
permitted exclusively for FSMP.
The Association  of the Food Industries for Particular Nutritional  Uses of the European Union
(IDACE)  has requested  an amendment  of Directive 95/2/EC to include additional  additives for
use in foods for infants and young children in good health and for use in FSMP for the same age
group (2, 3, 4, 5). In some cases particular additives have been requested  for both categories
(good health and FSMP) and in other cases for just one category or the other. Some of the
requests to use the same additive in both categories  relate to use in products containing
hydrolysed  proteins  which have special technical  requirements (e.g. products for cow's milk
allergy).  Such products are marketed  as FSMP and./or as foods for infants and young children in
good health.
The Scientif,rc  Committee  for Food (SCF) has recently  given an opinion on the use of certain
colours for FSMP for young children aged 1216 months of age (6)- The present opinion covers
certain additives  other than colours, most of which are emulsifiers, stabilisers or thickening
agents. The additives  requested and the recommendations  of the Committee are listed in the table
'Summary of Recommendations' at the end of this opinion and are considered individually below.
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In considering  the request to use additional additives,  the Committee was mindful of the principle
set out in its earlier reports that it is prudent to keep the number of additives used in
foods for infants and young children to the minimum  necessary (7, 8). The Committee has
stressed in the past that there should be strong evidence of need as well as safety before additives
can be regarded as acceptable for use in infant formulae and foods for infants and young
children. The Committee continues to endorse these principles, but is aware, for reasons
explained below, that the nature of FSMP is such that they may require a wider range of additives
than those already  permitted for foods for infants and young children in good health and/or they
may require a higher level of addition of an additive already  permitted for foods for infants and
young children in good health. The Committee is also aware that, for historical  reasons, different
manufacturers  of FSMP have developed  products over long periods of time utilising different
additives which may nevertheless  have the same technological  function.  However, the
Committee  wishes to record that it is not always  easy to reach a view on the case of need.
FSMP for infants and young children  encompass a wide variety of different products in
powdered, liquid or semi-solid forms, each with a specific formulation and hence each with its
own technological  requirements. They are generally  either of the 'elemental' type (formulae
containing  free amino acids, glucose syrup or maltodextrin and a low fat content) or 'semi-
elemental'  type (containing  hydrolysed proteins, maltodextrin and fat), together with vitamins,
minerals  and trace elements. The fats and starches  used may also be unusual compared  with those
used in foods for infants and young children in good health. Thus the technological requirements
for additives  for FSMP may differ considerably  from those for foods for infants and young
children in good health.
Normal infant formulae based on cow's milk benefit from the inherent properties of the
ingredients  they contain, in particular whole proteins which act as efficient emulsifiers. Products
containing hydrolysed proteins, peptides or free amino acids lack the normal emulsiffing
properties  of whole protein and so the use of additives such as emulsifiers with a high
hydrophylic-lipophylic balance (HLB) value is necessary to enable lipids and carbohydrates  of
very high molecular weight to interact. This limits the separation of the fatty phase in ready-for-
consumption  liquid products, notably when products  are formulated with modified  fats.
The only thickening  agent or stabiliser which is permitted in infant formulae for infants in good
health is starch. Native starches tend to lose their thickening  properties when processed, cooled
and stored, Products  formulated with protein hydrolysates, peptides or free amino acids require
added thickening agents  and stabilisers to influence viscosity both during sterilisation and at room
temperature,  to avoid separation  of the various  elements  such as fibres in liquid feeds, and to
reduce the coalescence of fat globules, especially in products in liquid, ready-to-consume form
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also require  the addition of thickening agents which are adapted  to their special properties.
Against this background, the specific considerations of need for each of the additives requested
for foods for infants and young children in good health and for FSMP for the same age group
have been carefully considered  by the Committee. For each additive  requested  for FSMP, the
Committee was also informed  about the range of medical conditions requiring  such foods which
might contain that additive and the estimated  levels of intake of each additive in the various age
groups (2,3,4, 5).
It is to be noted that, unless otherwise  stated,  reference to FSMP in the following evaluations  is to
be understood  as covering FSMP intended for infants and young children from birth onwards.
Consideration of individual additives
Distarch phosphate (E-I412)
Distarch phosphate has been requested for use up to 10 g/1 (reconstituted  dry powders)  and 22 gll
(liquids) in infant formulae and follow-on formulae for infants and young children in good health
and in FSMP. It is a chemically  modified starch containing  less than 0.02% phosphorus  and is
used as a stabiliser,  thickening agent and binder. Infant formulae containing modified milk
proteins  or soy proteins  and insoluble salts (such as calcium) require a stabilising agent to prevent
protein precipitation  during sterilisation  or storage.  The Committee has been informed  (2) that
starches cross-linked with phosphorus, such as distarch phosphate,  have higher stability during
shear stress and heat sterilisation. The Committee notes that distarch  phosphate is included in the
list of additives  permitted by the Codex Alimentarius  in soya-based infant formulae (5 g/l) and in
hydrolysed  protein and/or amino acid based infant formulae (25 gll).
Distarch phosphate  was assigned an acceptable daily intake (ADD 'not limited' by the
FAO/WHO Joint Expert Committee on Food Additives (JECFA) in 1973 (10). Modified starches
for general  food use and for use in baby food were also considered  by the SCF in 1976 and in
l98l (l l). Both JECFA and the SCF have considered  the kidney lesions which occur in rats fed
high levels of modified  starches. They concluded  that the rat is a particularly  sensitive  species  for
pelvic nephrocalcinosis and the finding has little relevance for safety evaluation of modifred
starches in man, and JECFA confirmed  an ADI 'not specified'  (11, l2).In its report on weaning
foods (13), the SCF concluded  that use of distarch  phosphate singly or in combination with other
starches was acceptable up to a limit of 5 9/100 g. ln 1992, the SCF reviewed the suitability of
distarch phosphate for use in infant formulae  and concluded that distarch phosphate  should not
be permitted in infant formulae (8).
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action of pancreatic amylase but infants have a very low activity of this enzyme (14). Instead,
mucosal glucoamylase and salivary amylase  are sufficient in some infants to digest long-chain
glucose-polymers  (15). It has also been shown that infants are capable of digesting cooked native
starches from the age of one month (16). However,  large amounts  (40 glday) of starches in the
diet given to one-month  old infants resulted  in malabsorption and fermentative diarrhoea (16). It
has also been suggested  that undigested  starch in the gastrointestinal  tract may interfere with other
food ingredients resulting in failure to thrive in some infants (17). The SCF has concluded that
pre-cooked  or gelatinised  starch (but not native or chemically modified starches) can be added to
infant formula up to 2 9/100 ml, but not exceeding  30 % of the total carbohydrate  content  (7). An
addition of 2 g starch/l0O  ml corresponds to an estimated intake of l0 glday. Consequently,  there
is no wide margin between the permitted level of native starches and the level of 40 g starch per
day, where effects have been observed.
In vitro studies using human and rabbit pancreatic amylases and in vlvo studies in adult rabbits
show that the digestibility of waxy corn distarch phosphate  and native starches is comparable
(1S). This study may be of little relevance  for the digestibilty of modified starches in infants due
to low levels of pancreatic  amylase, but as pointed out in the opinion by the Committee in 1992
(8), the spectrum of activity of alpha-amylase  in saliva and pancreatic  secretion is the same since
the amino-acid sequence  is identical  (19). Nevertheless,  it is not known how the efficacy of the
alpha-amylase in saliva compares with the pancreatic  form due to possible  effects on the enzyme
of, for example, gastric  juice.
Conclusion:
In its 1992 opinion (8) the SCF recommended  distarch phosphate should not be permitted in
infant formulae because  the Committee would prefer to see direct evidence indicating that infants
can tolerate  the 2.5 Yolevel of modified  starches  then requested. The current  request is for use up
to 2.2 %. A concern was also raised that infants could develop fermentative diarrhoea or
modification  of the gut flora. No new information  on these aspects has been found. Furthermore,
the Committee is not persuaded there is a need for use of distarch phosphate in infant formulae
generally.  A case of need could be valid for formulae containing hydrolysed proteins (whether for
children in good health or FSMP), but at present the Committee has insufficient information to
reach a conclusion  on this point. In the meantime  the Committee does not consider that the use of
distarch phosphate  is acceptable in infant formulae,  follow-on  formulae fbr infants and young
children in good health or in FSMP.
Sodium citrate (E-33f) and potassium  citrate (E-332)
Sodium citrate and potassium  citrate have been requested for use from birth, either singly or in
combination  at levels up to 2 gl, n infant formulae and follow-on formulae for infants and
young childrerr in good health and in FSMP (2). The heating procedure fbr infant formulae  or
follow-on formulae made from cow's milk results in denafuration  and aggregation  of proteins. In
extreme cases the result is a phase separation of fat and proteins.
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improve  heat stability. During heat treatrnent casein in milk coagulates  due to surplus ionised
calcium.  The addition of sodium or potassium citrate complexes free calcium  ions, resulting in
decreased coagulation. The same technological  function can also be performed by sodium and
potassium  phosphates (see below) and all four additives have been requested so that alternatives
are available (e.g. in cases where no additional  phosphate load can be tolerated).  Sodium and
potassium  citrates are already permitted under Directive 95l2lEC in weaning foods at quantum
safi's levels for pH adjustment only (l), and under Directive gll3zIlEEC  as sources of nutrients
in infant formulae and follow-on formulae for infants and young children in good health (9).
Conclusion:
The Committee  considers  the use of sodium and potassium citrates are acceptable up to 2 gll,
either singly or in combination, in infant formulae and follow-on formulae for infants and young
children in good health and in FSMP.
Sodium phosphate (E-339) and potassium  phosphate (E-340)
Sodium  phosphate and potassium  phosphate have been requested for use from birth, either singly
or in combination,  at levels up to I g/l (expressed  as PrOr), in infant formulae and follow-on
formulae  for infants and young children in good health and in FSMP (2). Their technological
function is the same as that for sodiurn and potassium citrates (see above). The use of sodium
and potassium  phosphates in weaning foods and cereals for infants and young children  is
permitted under Directive 95l2lEC, either singly or in combination  up to a maximum of I g/kg
(expressed  as P2O5) (l). These additives are also permitted  as nutrients in infant formulae  and
follow-on  formulae  under Directive  gll32llBBc  (7, 9). In 1992, the Scientific Committee  for
Food also concluded that the use of phosphoric acid (E-338) in infant formulae was acceptable
(8).
Sodium phosphate and potassium  phosphate were evhluated by JECFA in 1982 (12). Of greatest
concern  was the toxicity arising from excess of phosphorus (P) in the diet and deficiencies in
calcium (Ca). A high dietary phosphate intake in animals results in hypocalcaemia  which
stimulates  secretion of parathyroid hormone. This hormone inhibits tubular  reabsorption  of
phosphates by the kidney and increases demineralisation of bone tissue. P is mainly excreted in
iur.". as calcium phosphate, so that intake of excessive amounts of sodium  phosphate and
phosphoric acid may cause a loss of Ca. The main toxicological  finding in animal feeding studtes
with phosphates is nephrocalcinosis, the rat being highly susceptible.  An estimate  of the lowest
level of dietary intake of phosphates (expressed as P) that might cause nephrocalcinosis  in man is
about 7 000 mg Piday. Since P is an essential  nutrient, JECFA allocated a maximum tolerable
daily intake (MTDI) rather than an ADI. The MTDI of 70 mg/kg b.w. applies to the sum of
phosphates naturally present in food and derived from additives in the diet, for diets that are
nutritionally adequate  with respect to Ca (12).
Old data indicate that high-phosphorus  human milk substitutes  may contribute to hypocalcaemic
tetany in infants.  However,  when artificial formulae simulated breast milk, the occurrence of
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in cow's milk is 1.35:1 and in human milk 2.25:1. On the other hand, infants absorb 85-90 oh of
the P in human milk and 65-70 a/o of that in cow's milk (21).
The RDA (recommended dietary allowance)  for P for formula-fed infants from birth to six
months of age is 300 mglday, and 500 mglday for infants aged 6-12 months  (21). Allowances  for
P are based on a Ca:P ratio of 1.3: 1 (the same as in cows' milk) during the first six months of life
and I .2:l for the following  six months. Thus, for newbom infants, the RDA is around  the same
level as the MTDI for adults. The Committee therefore  considers that the MTDI as an upper limit
is not applicable  to infants.
At the requested level of I nl for E-339 and E-340 (expressed as P2O5), the P content  of formula
would be 440 mg P/l (P is 40 % of phosphate).  The mean consumption of infant formula is 700-
850m1/day in infants aged l-3 months, with a range of 500-1100mVday (22), and the 90th
percentile consumption is about 1 000 mUday. Thus, the estimated 90th percentile  intake of P
from use of E-339 and E-340 would be 440 mg P/day. This represents  150 % of the RDA.
Conclusion:
The estimated  90th percentile intake of P, although above the RDA for infants, is unlikely to be
harmful. While knowledge about toxicity from P intake in infants is limited, there are no
indications that there would be adverse health effects at the intakes resulting from the use of E-
339 and E-340 at the requested  level, provided the Ca:P ratio is kept within the recommended
limits set out in Annex I to Directive  911321/EEC  (9). The Committee  considers the use of
sodium phosphate and potassium phosphate, either singly or in combinatiof,, up to I gll
(expressed  as PzOs) is acceptable in infant formula, follow-on formula and FSMP.
Locust  bean gum (E-410)
Locust bean gum has been requested for use in infant formulae and follow-on formulae, both for
infants and young children in good health and in FSMP, at levels of 4-10 Vl, to reduce  gastro-
oesophageal reflux (GOR).  Locust bean gum, also called carob bean gum, is refined from the
endosperm of the carob tree, Ceratonia siliqua. It contains tannins and the carbohydrate
component  is a galactomannan polymer consisting of linked D-mannose  units with side chains of
D-galactose.  It is used as a stabiliser and thickening  agent. It is currently allowed in follow-on
formulae at a maximum level of 1 gil, and in weaning foods at a maximum  level of l0 g/kg under
Directive  95l2lEC (1). The SCF has previously  considered  a request to use locust bean gum at a
level of I gll in infant formulae but at that time there was no confirmation  of need (8).
The Committee is aware that some medical  specialists  (Espgan) recommend that thickening of
foods is useful in the treatment of GOR, and that in cases of uncomplicated GOR, treatment  with
thickening agents rnay be started without complementary  investigations  (23). Clinical
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formula in the concentration  range 4-I0 gll (2). However, there are few controlled studies of the
efficacy of use of thickened infant formula in reducing GOR. It is believed that the increased
viscosity of thickened feed will reduce the episodes of reflux, but it has been shown that the
effects  are unpredictable (24,25,26). Thickeners  added to infant formula may reduce the number
of reflux episodes,  but may also prolong the duration of remaining episodes (27). Increased
coughing in infants after thickened feedings compared  with after unthickened feedings  has also
been reported  (28).
Locust bean gum was evaluated by JECFA in 1981 (29). An ADI not specified  was allocated  due
to lack of toxicity. In an unpublished three-generation  reproduction study referred to by JECFA,
significant  decreases  in prernating body weight gain in the F0 females fed 2 o/o locust bean gum,
and final body weight in the females fed 5 %o locust bean gum were observed.  No significant
effect on body weight gain was observed in newly weaned  rats fed a diet containing 2 o/o locust
bean gum for 36 days (30). On the other hand growth was depressed in chickens fed a diet
containing 2 o% locust bean gum for 24 days (30). Thus there are indications of growth depression
in animals fed locust bean gum, although  these  are equivocal.
Bean gum preparations are fermented in the colon, providing a small energetic  gain. They can
cause abdominal pain and diarrhoea (23). Absorption of minerals  and trace elements may be
reduced by dietary frbre and tannins. Although a study on adults ingesting locust bean gum has
shown no evidence  of impaired absorption of minerals and trace elements  (31), it is not always
appropriate to use results from adults when evaluating health effects in infants in cases where
growth may be affected.  In rapidly  growing healthy infants, even minor effects on gastrointestinal
absorption of trace elements  and minerals may have growth retarding effects. Studies on growth
in healthy infants  chronically  exposed to locust bean gum are lacking.
Conclusion:
The Committee is not persuaded that it is necessary to give thickened infant formula to infants in
good health. It therefore recommends  that the use of locust bean gum is not acceptable,  at the
do..r requested, for use in infant formulae and follow-on formulae intended for infants in good
health. The Committee does, however, accept that there is a case of need for its use in FSMP to
treat GOR and recommends that its use in these products  up to 10 g/l is acceptable.
Mono- and diglycerides  of fatty acids (E-471)
Use of this emulsifier  has been requested for FSMP at levels up to 5 g/1 in powdered and liquid
formulations intended for infants and young children from birth onwards (2). It is currently
permitted under Directive 95l2lEC in infant formulae and follow-on formulae for infants in good
health up to 4 gll andin weaning foods for infants and young children in good health up to 5 g/kg
(1). The Committee has been informed (2) that a slightly higher level of E-471 is required,  for use
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FSMP which contain fat requiring an emulsifier of intermediate  HLB value.
This emulsifit'r  has not previously been individually considered by the SCF. The basic EC
directive on emulsifiers, stabilisers,  thickeners and gelling agents for use in foodstuffs  (32) was
agreed in 1974, before  the SCF was constituted. That directive permitted over 65 additives, sorne
temporarily.  T'he first SCF report on emulsifiers,  stabilisers, thickeners and gelling agents (33)
published in 1978, explains  that the Committee was asked to review only certain of the additives
in the directive. The review included theE-472 group of emulsifiers  but did not include E-471.
However, since the E-472 group are derived from E-471 (they are the acetic, lactic, citric, tartaric
and diacetyl tartaric acid esters of mono- and diglycerides of food fatty acids), it can be assumed
that the SCF rvas content  to go along with the acceptable daily intake (ADI) 'not lirnited' for E-
471, confirmed by the FAO/WHO Joint Expert Committee on Food Additives (JECFA)  rn 1974
(34).
Conclusion:
The Committee considers  that the use of E-471 is acceptable  at levels up to 5 gll in all
FSMP.
Citric acid esters of mono- and diglycerides  of fatty acids (E-472c)
This emulsifier has been requested for use from birth onwards  in dry formulae up to 7.5 g/l and in
UHT-liquid  formulae up to 9 g/1 which contain partially or extensively hydrolysed proteins both
for infants and young children in good health and for FSMP (2). Under Directive 95l2lEC, it is
not currently  permitted  for use in infant formulae  or follow-on  formulae for children in good
health but is permitted  up to 5 ilkg in weaning foods for children in good health (1). The
Committee has been informed  (2) that E-472c is needed, in addition  to the emulsifiers  already
permitted,  for products based on hydrolysed  proteins or amino acids with high levels of fat,
requiring emulsifiers with high HLB value.TheE-472 series of emulsifiers has high HLB values.
In its 1978 review (33), the SCF concluded that the use of E-472c was acceptable for foods
generally and, in effect, endorsed the ADI set by JECFA rn 1974, allocating an ADI 'not
specifi ed' for ll,-47 2c (34).
Conclusion:
The Committee  considers that the use of E-472c is acceptable in products  which contain  partially
hydrolysed  proteins for infants and children in good health and for FSMP containing extensively
hydrolysed  proteins  or amino acids at levels up to 7,5 g/l in ready-to-feed  products  made from dry
powder  and up to 9 gll in ready-to-use  UHT-liquid formulae.
Diacetyl tartaric acid esters of mono- and diglycerides  of fatty acids (n-472e)
This emulsifier,  also known as DATEM, has been requested for use from birth onwards up to
3 gll in reconstituted  powders and up to 4 gll in liquid formulations  which are devoid of whole
protein, both for children in good health and for FSMP, and up to 5 gikg in gluten-free  bakery
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forrnulae or weaning foods for infants and children in good health (l). The Committee has been
informed  (2) that it is a suitable ernulsifer, in combination with other already permitted
emulsifers, for hydrolysed  protein, peptide and amino acid-based  products, having very large
hydrophilic  polar groups which are pafiicularly suitable for multi-component  systems.
In its 1978 review, the SCF concluded  that the use of DATEM was acceptable for foods
generally  and, in effect, endorsed  the ADI set by JECFA in 1974, allocating an ADI of 0-
50 mg/kg b.w. (33). The SCF has now updated its view on DATEM  and, for reasons  explained  in
u *"purut  opinion  (57), has withdrawn  the ADI of 0-50 mg/kg b.w. and set a ternporary  ADI of
0-25 mg/kg b.w.
Conclusion:
The Committee ternporarily  accepts the use of DATEM in FSMP, but at a lower level than that
requested  for foods which are given as liquid formulations (whether  reconstituted  from dry
powder or from liquids).  The use of DATEM is temporarily  acceptable for a period of two years
at levels up to 0-4gll, as consumed,  in FSMP which are devoid of protein,  and up to 5glkg in
gluten-free bakery products for coeliac patients. The Committee is aware that a limit of 0.4 gll
may still mean that some infants and young children could exceed the temporary ADI of G-25
*g7tg b.w. However,  the Committee  has also taken into account the essential  nature of these
fjfr4p for infants and young children with certain diseases  and the considerable technical
problems in manufacturing these FSMP. Furthermore,  the Committee will review the situation in
iro y.urr' time. In the meantime the use of DATEM in foods for infants and young children in
good health is not acceptable.
Sucrose esters of fatty acids (E-473)
Sucrose  esters of fatty acids have been requested  for use as an emulsifier up to 120 mgil in
powdered and liquid FSMP containing partially or fully hydrolysed proteins or amino acids for
infants and young children from birth onwards,  and in liquid infunt formulae and follow-on
formulae containing partially hydrolysed or fully hydrolysed  proteins for infants and young
children in good hialth (2)- They have been permitted as an emulsifier in the EU in foods
generally  (except for bread unless authorised for that use nationally) since 1914 (32) and in
Iietetic ioods 1Js;. rney are not currently  on the list of permitted additives for foods for infants
and young children in good health.
Sucrose  esters of fatty acids were evaluated by the SCF in 1992, when a group ADI of 0-
Z0 mglkgb.w. (expressed as sucrose  monostearate)  was allocated  for sucroglycerides  and sucrose
esters deiived from palm oil, lard and tallow fatty acids, subject to a specification which would
limit the presence oi t.tru- and higher esters to no more than 7 % (36). This opinion was based
on information that the lower fatty acid esters of sucrose are hydrolysed  in the gut to the
constituent fatty acids and sucrose,  which are well-known  cornponents of food. It has been
considered  several times by JECFA and, in its most recent evaluation in 1995, also given an ADI
of 0- 20 mgikg b.w.
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esters of fatty acids are gastrointestinal  disturbances (soft stools, diarrhoea,  flatulence and
bloating) seen at intakes of 70 mg/kg b.w./day, with a no-effect level of 35 mg/kg b.w./day.
Intake estimates from the use of E-473 in ready-to-use  liquid formulae used as FSMP for infants
and young children from birth up to three years of age range from 15-20 mgkg b.w./day, which
is just within the ADL IT is unlikely that the ADI for E-473 would be exceeded on a regular basis
since E-473 is not permitted in other foods specially  prepared for infants and young children.
Conclusion:
The Committee  considers that the use of sucrose esters of fatty acids is acceptable up to 120 mg4
in powdered  and liquid FSMP containing extensively or fully hydrolysed proteins or amino acids
for infants and young children, and in liquid infant formulae and follow-on formulae containing
partially  hydrolysed  proteins  intended for infants and young children in good health.
Sodiurn alginate  (E-401)
Sodium alginate has been requested as a stabiliser to be used in FSMP up to a level of I g/1, in
products intended for infants and young children with metabolic disorders and for general  tube-
feeding  from six months of age onwards  (2). The Committee has been informed (?) that its use in
combination with other stabilisers  and emulsifiers reduces the overall intake of any one additive
in products Ibr metabolic disorders,  and in tube feeds its use in combination with other
thickeners  and gelling agents prevents separation of fibre in the liquid feed.
The SCF has already recommended  that sodium alginate is acceptable  as an additive in weaning
foods for infants and young children in good health, for use in desserts  and puddings at levels up
to 0.5 g/kg (8). It is permitted for these uses under Annex VI of Directive 95l2lEC (1). It has a
JECFA group ADI 'not specified' for alginic acid and its ammonium,  calcium,  potassium and
sodium salts (38). No estimates of intake for E-401 are given in the various submissions but
intakes from FSMP would almost certainly be higher than that from its use in desserts  and
puddings for infants and young children in good health. A worst case estimate,  assuming  that the
products  concerned are the sole source of nutrition and consumption of I 000 ml of product at six
months rising to 2 000 ml of product by three years of age, gives intakes of 130-140 mglkg
b.w./day for E-401.
Conclusion:
The Committee considers  that the use of sodiurn alginate is acceptable up to a level of I g/l in
FSMP used from four months of age onwards.
Propane-ln2-diol  alginate  (E-405)
Propane-1,2-diol alginate has been requested  as a stabiliser  for use up to levels of 0.2 gll in
FSMP intended  for young children from one year of age onwards who have cow's milk
intolerance  or inborn erors of metabolism (2). The Committee has been informed  (2) that it has
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acidic products  containing fat, which means  that citrus flavouring  may be added to mask the bitter
taste of amino acids. It is permitted under Annex IV of Directive 95l2lEC in a varief of
foods including  FSMP (for children over 3 years of age and adults) up to 1.2 gll, but is not listed
in Annex VI which covers food additives  permitted for infants and young children (l).
E-405 was listed in the basic I974 EEC directive on emulsifiers, stabilisers, thickeners  and gelling
agents for use in foodstuffs (32) but the SCF did not review E-405 until 1990 when an
ADI of 0-25 mglkg b.w. was allocated (39). JECFA allocated it an ADI of G-70 mg/kg b.w. in
1993 (40). Estimated  intakes of E-405 from nutritionally complete  FSMP are 2617 mg/kg
b.w./day for children aged 12-36 months  (2), which is marginally  above the SCF ADI and below
the JECFA ADI. Alginates in general and propane-1,2-diol  are of low toxicity and regular
consumption  just above the ADI would not be expected to pose any health problems.
Concluston:
The Committee  considers that use of propane-1,2-diol  alginate is acceptable up to levels of
0.2 gll in FSMP  intended for young children from one year upwards'
Carrageenan  (E-407)
Carrageenan has been requested for use in FSMP at levels up to 0.3 gil in ready-to-use liquid
formulae given from birth onwards which contain extensively hydrolysed protein and/or amino
acids (2). In these products it acts to increase viscosity,  delaying fat separation  and so giving  a
longer shelf life. The products concerned  are for children with intractable diarrhoea and other
malabsorption  conditions and with inborn errors of metabolism (2).
ln 1994 carrageenan was regarded by the Committee as not acceptable for use in infant formulae
for infants in good health (8) and is currently being reviewed again by the SCF in relation to food
use generally.  The Committee  currently has serious reservations about its use in very young
infants because of possible uptake by the immature  gut and the possibility of effects on the
immature imrnune system. In the context of FSMP, the Committee notes that medical conditions
affecting the permeability  of the gut may be of particular importance in any safety consideration'
So while the SCF did agree in 1983 that the use of caffageenan  was acceptable  at levels up to
0.3 gil in follow-up milks which may be given from four months of age onwards  (7), it has more
recently stated (8) that it wishes to defer its opinion  on the use of carageenan in weaning foods
and may wish to reconsider  its earlier opinion  on follow-on formulae in the light of the ongoing
review mentioned  above.
Conclusion:
The Committee is unable to offer an opinion on the acceptability  of the use of carrageenan in
FSMP until its current review on calrageenan is completed.
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Guar gum has been requested for use in FSMP at levels up to 10 g/1 from birth and20 g/l from 6
months of age in ready-to-use liquid formulae which contain extensively  hydrolysed  protein
and/or amino acids, and for use at levels up to I g/l in ready-to-use liquid formulae  containing
extensively hydrolysed proteins used from birth for infants in good health. In these products it
acts to increase viscosity, delaying fat separation and so giving a longer shelf life. The FSMP are
intended for children with intractable diarrhoea, other malabsorption conditions,  impairment  of
the gastrointestinal  tract, protein intolerance  or inborn effors of metabolism.
Guar gum has a JECFA ADI 'not specified' (34), The SCF has already agreed that the use of
guar gum is acceptable at levels up to I g/1 in follow-up milks which may be given from four
months of age onwards  (7) and at levels up to l0 g/kg in all weaning foods and up to 20 glkg in
gluten-free,  cereal-based  weaning foods (13). These uses are all included in Annex VI of
Directive  95l2lEC (l). In its 1994 opinion on infant formulae, the SCF reserved its view pending
confirmation by the industry of essential need and also noted that no multi-generation  study was
available (8). The Committee  further notes now that guar gum contains a significant protein
fraction and that true allergy to guar gum via inhalation and subsequently  the oral route has been
recorded in exposed  workers. The Committee  therefore  considers that guar gum is not suitable  for
use in liquid formulae for any age group in infants and young children suffering from protein
intolerance,  unless it can be shown that the products concemed comply with the conditions  set
out for products claiming reduced allergenic  properties  in Annex IV of Directive 911321/EC (9) as
amended  by Commission  Directive96l4lEC (56).
Conclusion:
Guar gum is acceptable for use in FSMP from birth onwards,  at levels up to 10 glltnready-to-use
liquid formulae which contain extensively hydrolysed protein and"ior amino acids, and at levels up
to I gll in ready-to-use liquid formulae  containing  partially  hydrolysed  proteins for infants in
good health, provided that in the case of products intended for infants and young children with
protein intolerance,  the addition of guar gum does not jeopardise compliance with the conditions
set out for products claiming  reduced  allergenic properties in Annex IV of Directive gll3zllBc
(9) as amended  by Commission Directive  96l4lEC (56). The Committee requires  further technical
justification for the need to use amounts higher than 10 gll in FSMP and in the meantime  no more
than 10 g/l should be used.
Xanthan gum (E-415)
Xanthan gum has been requested for use in FSMP at levels up to L2 gll in products based on
amino acids and peptides  given from birth onwards (2). The Committee has been informed (2)
that in these products, some of which are fed by tube, it acts in combination with guar gum to
prevent sedimentation of components with low water solubilty,  such as fibre. The products
concerned are for children with impairment of the gastrointestinal tract, protein malabsorption or
inborn errors of metabolism.
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(al). This was based on lack of toxicity in animal feeding studies and observations  in rnan and the
then proposed levels of use (l-5 g/kg in foods and 0.5 gllin beverages). The SCF has also agreed
that the use of xanthan gum is acceptable at levels up to 10g/kg in all weaning foods and up to
70 gkg in gluten-free, cereal-based weaning foods (13) and these uses are all included in Annex
VI of Directive 95l2lEC (1). It has a JECFA ADI 'not specified' (34). There are no reasons to
indicate  it is unsuitable  for infants from birth onwards.
Conchtsion:
The Cornmittee  considers that xanthan gum is acceptable for use at levels up to 1 .2 gllin FSMP,
Pectin (E-440)
Pectin has been requested for use in FSMP in liquid and dry formulae  at levels up to l0 g/l in
ready to feed form for products  given from birth onwards  for those with diarrhoea resulting from
gastrointestinal disorders  (2). The Committee has been informed  (2) that in these products  it acts
both as a gelling/thickening  agent to delay gastric emptying and serves a physiological  function  as
soluble dietary fibre.
The SCF has already agreed that the use of pectin is acceptable  at levels up to l0 glkg in all
weaning  foods and up to 20 g/kg in gluten-free, cereal-based weaning  foods (13) and is acceptable
in follow-on formulae  up to 5 g/1 (8). These uses are all included  in Annex VI of Directive
gslzlBc (1). In its opinion on infant formulae where the level of addition requested was I g/1, the
SCF has reserved its view pending confirmation  by industry of essential need (8). The SCF has
endorsed  (33) the JECFA ADI 'not specifred' (10) and there are no reasons to indicate it is
unsuitable  for infants  from birth onwards.
Conclusion:
The Committee  considers that pectin is acceptable for use at levels up to 10 g/1 in FSMP.
Sodium carboxymethyl cellulose (E-466)
Sodium carboxymethyl  cellulose has been requested  for use in FSMP at levels up to l0 g/1 in
liquid foods given frorn birth onwards  and at levels up to 10 gikg in solid foods. These products
are intended for metabolic  disorders, such as inborn effors of fatty acid metabolism  (2). The
Committee has been informed (2) that it acts as a thickening, gelling  and solvation agent resulting
in a less 'sandy' mouth feeling.
The SCF has allocated  an ADI 'not specified'  for modified celluloses  as a group which included
E-466 (42). The Committee  earlier reserved its opinion on a request to use E-466 in weaning
foods pending completion of its work on persorption of macromolecular additives but noted that
otherwise  the toxicological  data did not indicate any effects likely to be of concern  for infants and
young children over weaning  age (8). However,  the Committee  has since been informed that
sodium carboxymethyl  cellutose in water is in colloidal form and hence is not likely to be
persorbed.
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The Commiffee considers that use of sodium carboxymethyl  cellulose is acceptable in FSMP at
levels up to 10 dl in liquid foods and at levels up to 10 g/kg in solid foods.
Glycerol (E-422)
The use of glycerol  at quantum  salrs levels has been requested as a non-cariogenic substitute for
sugar as a sweetener in concentrated juices based  on vegetables and fruits, especially intended  for
young children. Proposed levels are 5-15 o/o in ready-to-drink products. Glycerol  would also play
a role as a preservative  and as a solvent  in such drinks (5).
Sweeteners are regulated under Directive 94B5nC and glycerol is not included  in the list of
permitted sweeteners (43). Moreover, Article 2.3 of 94/35lEC states that sweeteners shall not be
used in foods intended for infants or young children. Other low-calorie  sweeteners,  such as
polyols, are not permitted in food for children under three years of age. The use of food additives
in fruit juice in general is also restricted  under Directive 95l2lEC, Annex II (1).
JECFA allocated an ADI 'not specified' in 1976, based on the daily intake of glycerol arising
from its use, at the levels necessary to achieve the desired effect (aa). The SCF agreed with this
view and considered glycerol acceptable for use as a solvent in food (45).
Glycerol is rapidly absorbed after ingestion and readily metabolised. It can be converted to fat,
shunted into glucose or glycogen  synthesis or broken down by glycerokinase in the liver to carbon
dioxide and water. Glycerol  is reabsorbed in proximal tubuli,  and is thus not normally present in
urine. However, in the case of a glycerol overload  it appears  in the urine (46).
Due to its pharmaceutical  uses, the adverse effects of glycerol in humans have been studied. They
are primarily due to its dehydrating  action. The major effects of oral glycerol in otherwise  healthy
patients  are headache,  nausea  and vomiting g7). Less frequently diarrhoea,  thirst, dizziness,  and
mental confusion can occur. Cardiac anhyhmias have also been reported.  Mild osmotic diuresis
occurs after oral doses of l 0-1.3 g glycerol/kg b.w. (46).
Following oral administration  of 0.75-1.5glkg b.w. in a 50-75  %o solution, a relatively rapid
increase in serum osmolality occurs, leading to a reduction of intraocular and intracranial pressure
(48,49). This dose level is used as treatment for acute glaucoma  in children as well as adults. The
effect on intraocular  pressure may last for 4 to l0 hours (48).
Thirfy minutes after ingestion of glycerol at a dose of I g/kg b.w. the intracranial  pressure was
four times lower than before glycerol administration, and normalised after 4 hours (50).
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49). The absorption of glycerol is insulin-independent  (51). In an insulin-deficient organism
glycerol is converted  to glucose. Two thirds of this glucose is metabolised  in the Kreb's cycle and
the remaining one third is released into the circulation.  Glycerol  administered  orally increases  the
blood glucose  level slightly in diabetic and minimally in non-diabetic patients.  In addition, when
glycerol is substituted  as energy equivalent for glucose, it may reduce the blood glucose level and
cause hypoglycaemia in diabetics receiving insulin (52). An insulin-dependent man was given
120 ml of 50 o/o glycerol-solution (i.e. 0.9 g glycerol/kg  b.w.) twice during 24 hours as treatment
for neovascular glaucoma (51). The patient  developed hyperosmolar non-ketonic  coma due to
dehydration. Since potassium deficiency  may accompany  diuresis, it is also advised that
individuals with congestive  heart disease,  hepatic or renal disorders  should be monitored carefully
when exposed to glycerol.
The proposed  level of addition of glycerol is 5-15 o/o in ready-to-drink  products. At the higher
level of addition,  a child three years of age, weighing 15 kg, and drinking 200 ml juice would
ingest 2 g glycerollkg b,w. Thus the amount of glycerol that might be consumed from the
proposed use is comparable  to the doses used when treating acute glaucoma.  The juice
concentrate  would contain 65 g glyceroVl00  ml according to the applicant (5). A three-year-old
child ingesting one to two tablespoonfuls of juice concentrate  would be exposed to about I g
glycerol/kg b.w.
Conclusion:
The adverse  effects reported in non-diabetic  patients occur at oral exposure levels which are
similar to those which could be consumed  as a result of the proposed  concentrations  in ready-to-
drink products. The safety margin, if any, is small compared to exposure levels where the
dehydrating  effects of glycerol are apparent. In addition, oral glycerol at these intakes in
combination with diabetes may have severe consequences.  Since low-sugar products are often
selected by patients  with diabetes, its proposed  use seerns particularly undesirable.  The reported
mild diuretic  effect of glycerol might also worsen the condition  of a child already  dehydrated by
infection or other diseases.  The Committee considers  that the use of glycerol  is not acceptable in
juices intended for young children.
Sodium-L-ascorbate  (E-30 I )
Sodium-L-ascorbate  has been requested for use as an antioxidant in coatings of nutrient
preparations  containing polyunsaturated  fatty acids which are used in infant formulae and follow-
on formulae for infants and young children in good health and in FSMP for the same age group'
The amounts used would give levels up to 75 mgll (expressed as ascorbic  acid) in final foods (5,
53), The maximum  level of addition requested is the same as that already  permitted for addition
of sodium-L-ascorbate as a dietetic additive to infant formulae and follow-on formulae' It is
already permitted in certain weaning  foods up to 0.3 g/kg under Directive 95l2lEC (l).
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The Committee considers  sodium-L-ascorbate to be acceptable  as an antioxidant  in coatings of
nutrient preparations containing  polyunsaturated fatty acids in infant formulae and follow-on
formulae for infants and young children in good health and in FSMP for the same age group,
provided total levels in final food do not exceed 75 mgll.
L-ascorbyl palmitate (E-30a)
L-ascorbyl palmitate has been requested as an antioxidant, for use in combination  with
tocopherols, at up to 10 mg/l in infant formulae and follow-on  formulae  for infants and young
children in good health and at corresponding levels in FSMP for the same age group(2). It is
already permitted in certain weaning  foods up to 0.1 glkg under Directive  95l2lEC (l). The
Committee has previously  examined  the use of L-ascorbyl  palmitate in the context of approved
nutritional  substances  and technological additives  (7, l3).
Conclusion:
The Committee  considers L-ascorbyl palmitate to be acceptable as an antioxidant up to l0 mg/l in
infant formulae  and follow-on  formulae for infants and young children in good health and at
corresponding  levels in FSMP for the same age group.
Calcium citrate (E-333)
Calcium citrate has been requested at quantum salis levels for use as a firming agent in fruit-based
products, with a low sugar content in which low ester pectins have to be used, for infants
and young children in good health. The Committee  has been informed that addition of extra
calcium ions achieves  proper gel formation with low ester pectins. Calcium citrate dissolves
slowly in the product donating calcium  ions and is preferable to other, more rapidly dissolving
calcium  salts. The actual use level would depend on the calcium present in the fruit and could
range from 100-1 000 mglkg of product, coffesponding to l-0-25 mg added Calg added pectin
(5). Calcium citrate is already permitted at quantum safis levels as a pH adjuster in weaning foods
under Directive 95l2lEC (1). It is also allowed as a source of nutrients in cereal based weaning
food and baby foods under Directive  96l5lEC (54\.
Conclusion:
The Committee considers  the use of calcium  citrate in fruit-based baby fbods with a low sugar
content is acceptable provided the amounts  added do not exceed the maximum  limit for calcium
for this category of foods set out in Article 5 of 96l5lEC (54).
Tricalcium  phosphate (E-341)
Tricalcium  phosphate has been requested as a firming agent for use in combination with pectin to
improve gel formation in fruit desserts for infants and young children in good health (4) Calcium
salts of orthophosphoric acid are permitted sources of nutrients in weaning foods under Directive
gllS2IlEEC (9, 13) and in cereal foods and baby foods under Directive 96l5lEC (54). It is also
52 Reports of the Scientific  Committee  for Food (43rd series)permitted  as an additive in weaning foods up to I gkg (expressed  as P2O5), either singly or tn
combination with other phosphates, under Directive 95l2lEC (l).
Conclusion:
The Committee considers that the use of tricalcium  phosphate up to a maximum level of I g/kg is
acceptable as a firming agent in fruit desserts for infants and young children in good health.
Acacia gum (E-414)
Acacia gum, also known  as gum arabic, has been requested for use in nutrient preparations,  up to
a level of 150 g/kg, as a coating for vitamins and trace elements  added to infant formulae  and
follow-on formulae for infants and young children in good health and for FSMP for the same age
group (2). It is required in the coating to prevent oxidation of the vitamins and in the case of
certain  trace elements to prevent them causing peroxidation of unsaturated fatty acids with which
they may come in contact (2). The Committee has already  considered  the use of acacia gumigum
arabic in coatings for vitamin preparations and concluded that use resulting in a low level of
carry-over of 10 mgikg in infant formulae, follow-on formulae and weaning  foods was
acceptable (55). The same level of addition to the coating of trace elements has been requested as
was previously  requested for the coating of vitamins (150 g/kg of nutrient preparation). Acacia
gum is currently  permitted  as a direct additive in weaning foods up to l0 mg/kg and in gluten-
free, cereal based foods up to 20 mg/kg (9, 1).
Conclusion:
The Committee considers that the use of acacia gum/gum arabic in coatings for nutrient
preparations  containing trace elements is acceptable provided carry-over  levels in infant
formulae, follow-on formulae or FSMP do not exceed 10 mglkg,
Discussion
IDACE proposed that the additives  requested  be considered according to three categories of
product, that is, those which may be used from birth, those from the age of six months and those
from the age of one year, reflecting  the current market. FSMP can be introduced into the diet of
infants, alone or in association  with other foods, from the flrrst days of life. The Committee has
considered  each additive requested for use in FSMP from the health point of view in relation to
whether  their use is justified in the particular circumstances  of feeding infants and young children
suffering from particular medical conditions,  taking due account of the immaturity of
physiological  systems in the very young infant, especially in those below 12 weeks of age. For
ixample,  since protein hydrolysates may have to be used from birth, there should be no age
restriition  on the use of acceptable  emulsifiers with respect to infants who may be given them.
Similarly  the Committee sees no reason to make a special distinction  at six months of age instead
of four months of age. According to Council Directive gll3zllBc, 'infants' means  those below l2
months of age and 'young children'  those between 12 and 36 months of age (9).
s of the Scienti{ic Committee  for Food (43rd  series)FSMP  are intended for use for a very heterogeneous group of medical conditions and it should  be
noted that the views on safety which the Committee offers in this opinion can only be based on
general considerations  rather than considerations  of the precise nature of the various illnesses and
conditions for which they are intended for use.
Since the required levels of addition of emulsifiers  in FSMP may be relatively high for some
products,  the Committee has given careful  consideration  to whether it would be possible
regularly to exceed the ADI for any of the additives requested, in cases where a numerical ADI
has been allocated. This does not appear  to be the case.
Conclusions  and recommendations
The Committee's  recommendations  have been reached after consideration of each request  with
respect to the case of need, safety and nutritional requirements,  bearing in mind the need to keep
the number of additives in foods for infants and young children, whether sick or in good health,
to the minimum necessary. In the case of additives requested  for use from birth onwards, the
Committee was particularly conscious  of the physiological  situation in infants  and very young
children. The Committee draws attention to the fact that in some countries, products made with
hydrolysed proteins for infants and young children with protein intolerance are not marketed as
FSMP but as products for infants  and young children in good health.
The Committee's recommendations on the requested additives are summarised in the table
below. The opinion on acceptability  applies only to the uses and the maximum levels of use
specified,  It should be noted that in cases where the Committee has recommended  that the use of
an additive in FSMP is acceptable, this does not imply that its use in foods for infants and young
children in good health is also acceptable, unless so stated. Equally, a recommendation that an
additive is acceptable for use in foods for infants and young children in good health does not
necessarily imply that it is acceptable in FSMP. It follows that should the recommendations  in the
present  opinion be implemented in due course by amendment of Directive  95l2lEC, this may
require a change in the wording of Part 4 of Annex VI to the Directive, which currently  permits
all additives for infants  and children in sood health to be used in FSMP.
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Additive
Requested  products
and maximum level
of use
Opinion:  foods for
infants and young
children in good
health
Opinion: FSMP
for infants and
young children
Sodium-L-ascorbate
E-301
(Page  5 1)
In coatings  of NP
containing PUFA
added to IF, FOF,
FSMP. Level not to
exceed 75 mgA
(expressed as
ascorbic acid) in final
foods
Acceptable from birth
onwards for the
requested conditions
ofuse
Acceptable  from birth
onwards for the
requested conditions
of use
L-ascorbyl palmitate
E-304
(Page 52)
IF, FOF l0 mg/I,
FSMP at same levels
Acceptable  from birth
onwards for the
requested conditions
ofuse
Acceptable  from birth
onwards for the
requested conditions
ofuse
Sodium ciffate E-331
(Page 40)
IF, FOF, FSMP
2 gke
Acceptable  from birth
onwards for the
requested conditions
ofuse
Acceptable from birth
onwards for the
requested conditions
ofuse
Potassium citrate
E-332
(Page 40)
IF, FOF, FSMP
2 eke
Acceptable from birth
onwards  for the
requested conditions
ofuse
Acceptable from birth
onwards for the
requested conditions
of use
Calcium citrate
E-333
(Page 52)
WF quantum satis rn
low-sugar fruit-based
products
Acceptable  up to
limit for Ca in
96l5lEC for the
requested conditions
of use
N/R
Sodium  phosphate
E-339
(Page 41)
IF, FOF, FSMP
1 g/l expressed as
P2O5, provided Ca:P
ratio within limits in
9U32l1EEC
Acceptable  from birth
onwards for the
requested conditions
ofuse
Acceptable  from birth
onwards for the
requested conditions
ofuse
Potassium phosphate
E-340
(Page 4l)
IF, FOF, FSMP
I g/l expressed as
P2O5, provided Ca:P
ratio within lirnits in
9U32l|EEC
Acceptable  from birth
onwards  for the
requested conditions
ofuse
Acceptable  from birth
onwards  for the
requested conditions
ofuse
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Requested products
and maximum level
of use
Opinion: foods for
infants and young
children in good
health
Opinion: FSMP
for infants and
young children
Tricalcium phosphate
E-341
(Pase 52)
WF 1 g/kg in
fruit-based  desserts
Acceptable for the
requested conditions
ofuse
N/R
Sodium alginate
E-401
(Page 46)
FSMP 1 g/l N/R Acceptable from four
months  onwards for
the requested
conditions of use
Propane-1,2-diol
alginate E-405
(Page 46)
FSMP 0.2 gll N/R Acceptable from 12
months  onwards for
the requested
conditions of use
Carrageenan  E-407
(Page 47)
FSMP  300 mg/l N/R Opinion deferred,  not
acceptable in the
meantime
Locust bean gum
E-410
(Page 42)
IF, FOF, FSMP
10 g/l in products  for
reduction  of gastro-
oesoohageal  reflux
Not acceptable Acceptable from birth
onwards  for the
requested conditions
ofuse
Guar gum E-412
(Page 48)
IF, FOF 1 gil
FSMP l0 gl in liquid
formulae containing
hydrolysed  proteins,
peptides or amino
acids, 20 gll from six
months of ase
Acceptable  from birth
onwards  for the
requested conditions
of use provided infant
formulae comply
with conditions in
Annex IV of
9Il32l|EEC as
amended bv 9614/EC
Acceptable from birth
onwards for the
requested conditions
of use up to 10 g/1.
(20 gll not acceptable
pending  technical
justification)
Acacia gum E-414
(Page 53)
In coatings of NP
containing vitamins
and trace elements
added to IF, FOF and
FSMP. 150 glkg
inNP, carry-over
level not to
exceedl0 ms,ike
Acceptable  from birth
onwards for the
requested conditions
ofuse
Acceptable from binh
onwards  for the
requested conditions
ofuse
Xanthan  gum E-415
(Page 48)
FSMP 1.2 s.ll NiR Acceptable from birth
onwards for the
requested conditions
of use
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Requested  products
and maximum level
of use
Opinion:  foods for
infants and young
children in good
health
Opinion: FSMP
for infants and
young children
Glycerol E-422
(Page 50)
WF quantum satls in
concentrated juices
based on vegetables
and fruits
Not acceptable NiR
Pectin E-440
(Page 49)
FSMP 10 g/l NiR Acceptable  from birth
onwards  for the
requested conditions
of use
Sodium
carboxy-methyl
cellulose  E-466
(Page 49)
FSMP r0 gll (liquid)
l0 g/<g (solid)
NiR Acceptable  from birth
onwards  for the
requested conditions
ofuse
Mono- and di-
glycerides  of fatty
acids E-471
(Page 43)
FSMP 5 eil N/R Acceptable  from birth
onwards for the
requested conditions
ofuse
Citric acid esters ot
mono- and di-
glycerides  of fatty
acidsE-472c
(Page 44)
IF, FOF, FSMP
7.s slt (dry) 9 g/l
(liquid) containing
hydrolysed proteins,
peptides or amino
acids
Acceptable  from birth
onwards for the
requested conditions
ofuse
Acceptable  from birth
onwards for the
requested conditions
of use
Diacetyl tartaric acid
esters of rnono- and
di- glycerides  of fatty
acidsE-472e
(Page 44)
IF, FOF, FSMP
containing
hydrolysed  proteins,
peptides or amino
acids, 0.4 g/l (as
consumed). WF 5 g/l
in gluten-free bakery
products  for coeliac
patients
Opinion deferred, not
acceptable in the
meantime
Temporarily
acceptable from birth
onwards  for the
requested conditions
ofuse
Sucrose  esters offattv
acids E-473
(Page 45)
IF, FOF, FSMP
containing
hydrolysed proteins,
peptides or amino
acids, 720 mgll
Acceptable from birth
onwards  for the
requested conditions
ofuse
Acceptable from birth
onwards for the
requested conditions
of use
of the Scientific  Committee  for Food (43rd series)Additive
Requested products
and maximum level
of use
Opinion: foods for
infants and young
children in good
health
Opinion: FSMP
for infants and
young children
Distarch  phosphate
E-1412
(Page 39)
IF, FOF, FSMP
l0 gil (dry) 22 gll
(liquid)
Opinion deferred, not
acceptable in the
meantime
Opinion deferred
pending submission
ofcase ofneed, not
acceptable in the
meantime
Key to summary  table
IF  :  infant formulae  ) for infants and young
FOF :  follow-on formulae  ) children in
WF :  weaning foods  ) good health
FSMP:  foods for special medical  purposes
NP  :  nutrient preparations
N/R :  not requested
PUFA:  polyunsaturated  fatty acids
References
1.  European Parliament and Council Directive 9512/EC of 20 February 1995 on food
additives  other than colours  and sweeteners, OJ L 61, 18.3.1995, pp. l-40.
2.  IDACE, 'Requests and supporting  technological  justifications  for amendments to the
European Parliament and Council Directive 9512/EC of 20 February  1995 on food
additives  other than colours and sweetners',  CS/ADD/MsAdll26,  May 1995, unpublished
submission to the Scientiflrc Committee for Food, Paris.
3.  Scientific Hospital  Supplies International, 'FSMP other than colours and sweeteners:
additional information on emulsifiers. CS/ADD/MsAd/149,  September  1996',
unpublished  submission  to the Scientific Committee for Food, Liverpool.
Reports of the Scientific  Committee  for Food (43rd series)4.
5.
6.
8.
9.
10.
11.
t2.
IDACE, 'Additives for use in foods for infants and young children: background
information to IDACE submission, CS/ADDlMsAdll42,  July 1996',  unpublished
submission  to the Scientific Committee for Food, Paris.
IDACE, 'Additives for use in foods for infants and young children: glycerol  in fruit and
vegetable-based  drinks for young children  (E-422), calcium  citrate as a firming agent in
low sugar-based drinks for young children (E-333), sodium-L-ascorbate  as an antioxidant
in coatings of nutrient  preparations  containing polyunsaturated  fatty acids (E-301)',
CS/ADD/MsAd/138,  May 1996, unpublished submission  to the Scientific  Committee for
Food, Paris.
Scientific  Committee for Food, European  Commission,  'Opinion on colours in foods for
special medical purposes for young children (expressed on 13 December  1996)'
CS/ADD/COLll34-Final,  Annex VI to Minutes of the l05th Meeting of the Scientific
Committee for Food held on 12 and 13 December 1996 in Brussels, Document
IIV 5 | 5 6197, European Commission, Brussels,  1997 .
Scientific  Committee  for Food, European  Commission, 'First report of the Scientific
Committee for Food on the essential requirements  of infant formulae and follow-up milks
based on cows' milk proteins', Reports  of the Scientific Committeefor  Food, (I4th series),
Office for Official Publications of the European Communities, Luxembourg,  1983.
Scientific Committee for Food, European  Commission,  'Opinion on certain additives for
use in infant formulae, follow-on  formulae and weaning foods', Reports of the Scientific
Committee for Food, (32nd series), Offrce for Official  Publications  of the European
Communities, Luxembourg,  1 994.
Commission Directive gll3zIlEEC  on infant formulae and follow-on formulae, OJ L 175,
4.7.1991, pp. 35-49.
Joint FAOfiMHO  Expert Committee on Food Additives, Toxicological  evaluation of some
food additives including anti-caking agents, anti-m[crobials, anti-oxidants, emulsifiers
and thicken[ng  agents, WHO Food Additives  Series No 5, WHO, Geneva,  1974'
Scientiflrc  Committee  for Food, European Commission,  'second report of the Scientific
Committee for Food on modifred starches' , Reports of the Scientffic Committee for Food
(I3th series),  Office for Official Publications of the European Communities, Luxembourg,
1982.
Joint FAO/WHO Expert Committee on Food Additives, Toxicological evaluation of
certainfood additives,  WHO Food Additives  Series No 17, WHO, Geneva,  1982-
Reports of the Scientific  Committee  for Food (43rd  series) 5913.  Scientific Committee  for Food, European Commission, 'First report of the Scientific
Comrnittee for Food on the essential  requirements for weaning foods', Reports of the
Scientific Committee for Food, (24th series), Of{ice for Official Publications of the
European Communities, Luxembourg,  199 1.
14.  Lebenthal, E. and Schwachman,  H., 'The pancreas development, adaptation and
malfunction in infancy and childhood'  , Clinical Gastroenterologt,6,1977,397413.
15.  Shulman, R. J., Kerzner, B., Sloan, H. R., Boutton,  T.W., Wong, W.W., Buford, L. N.
and Klein, P.D., 'Absorption and oxidation  of glucose polymers of different lengths in
young infants', P ed iatric Re s earch, 20, 1986,  7 40-3 .
16.  De Visia, B., Ciccimarra, F., DeCicco, N. and Auricchio, S., 'Digestibility  of starches in
infants  and children'  , Journal  of Pediatrics,  36, 1975,50-5.
17.  Lilibridge,  C. B. and Townes, P.L., 'Physiological deficiency  of pancreatic amylase in
infancy: a factor in iatrogenic diarrhoea' , Journal of Pediatrics,  S2, I973,279-282.
18.  Lee, P. C., Brooks, S.P., Kim, O., Heitlinger, L. A. and Lebenthal, E., 'Digestibility of
native and modified starches: in vitro studies with human and rabbit pancreatic amylases
and in viuo studies in rabbits' , Journal  of Nutrition, Il5, 1 985, 93- 1 03  .
19.  Sevenhuysen,  G. P., Holodinsky, C. and Dawes, C., 'Development of salivary alpha-
amylase in infants from birth to five months', American Journal of Clinical Nutrition,39,
t984,584-9.
20.  Mizrahi, A., London, R. D. and Gribetz, D.,'Neonatal hypocalcaemia - its causes and
treatment',  New England  Journal  of Medicine,278,1968,  1163-5.
2I-  National Research  Council, Recommended  dietant allowances, 10th edition, National
Academy  Press, Washington  DC, 1989.
22.  Hofvander, Y., Hagman,  IJ., Hillervik, C. and Sjolin, S., 'The amount of milk consumed
by l*3 months-old  breast- or bottle-fed infants', Acta Paediatrica  Scandinavica,  71,
1982,953-9.
23.  Vandenplas,  Y., Ashkenazi, A., Belli, D., Boige, N., Bouquet, J., Cadranel,S. et al.,'A
proposition  for the diagnosis and treatment of gastro-oesophageal  disease in children: a
report from a working group on gastro-oesophageal  reflux disease',  European Journal of
Paediatrics,  | 52, 1993,  7 04-I I.
Reports of the Scientific  Committee  for Food (43rd series)24.  Bailey, D. J., Andres, J. M., Danek, G. D. and Pineiro-Carrero V. M., 'Lack of efficiency
of thickened feeding as a treatment for gastro-esophageal  reflux', Journal of Pediatrics,
110,1987,187-9.
25.  Vandenplas,  Y. and Sacr6, L., 'Milk-thickemng agents as a treatment for gastro-
oesophageal reflux', Clinical  P ediatrtcs, 26, 1987, 66-8.
26.  Vandenplas, Y., 'The diagnosis and treatment of gastro-oesophageal  reflux disease in
infants  and children'  , Annals of Medicine,25, 1993,323-8.
27.  Davies, A- E. M. and Sandhu, B. K., 'Diagnosis and treatment of gastro-oesophageal
reflux', Archives of Diseases of Childhood,73,1995,82-6.
28.  Orenstein,  S., Shalaby, T. M. and Putnam, P.8., 'Thickened feedings as a cause of
increased coughing when used as therapy for gastro-esophageal reflux in infants' Journal
of Pediatrics,  I2l, 1992, 9 I 3-1 5.
29.  Joint FAOAMHO  Expert Comrnittee on Food Additives, Twenty-fifth report of the Joint
FAO/WHO Expert Committee on Food Additives, WHO Food Additives  Series No 16,
WHO, Geneva, 1981.
30.  Vohra, P., Shariff, G., and Kratzer,  F. H., 'Growth inhibitory  effect of some gums and
pectin for Tribolium castaneum  lawae, chickens and Japanese  quail', Nutrition  Reports
International, 19, 1979, 463-9-
31.  National Research Council,'Diet and health: implications for reducing  chronic  disease
risk', National Academy Press, Washington DC, 1989,291-309.
32.  EEC Directive 14l329lEEC  of 18 June 1974 on emulsifiers,  stabilisers, thickening and
gelling agents for use in foodstuffs , OJ L 189, 12.7 '7974, p l.
33.  Scientific Committee  for Food, European Commission,  'Report of the Scientific
Committee for Food on emulsifiers, stabilisers,  thickening  and gelling agents', Reports of
the Scientific Committee  for Food, (Seventh  series), Office for Official Publications of the
European Comrnunities,  Luxembourg,  197 8.
34.  World Health Organisation,  Toxicological evaluation of certain food additives  with a
review of general principles  and of specifications, ITth Report of the Joint FAO/WHO
Expert Committee  on Food Additives, WHO Technical  Report Series No 539, WHO,
Geneva, 1914.
35.  Council Directive 89/398/EEC on foods for particular nutritional uses, OJ L  186,
30.6.1989,  pp.27-32.
Reports of the Scientific  Committee  for Food (43rd  series) 6r36. Scientific Committee for Food, European  Commission, 'Sucroglycerides  and sucrose
esters', Minutes of the 83rd Meeting of the Scientific Committee for Food held on l0
April 1992 in Brussels,  Document lIIl3280l92,  European Commission  DG III, Brussels,
1992.
World Flealth Organisation, Evaluation  of certain food additives and contaminants,  44th
Report of the Joint FAO/WHO Expert Committee on Food Additives, WHO Technical
Report Series No 859, WHO, Geneva,  1995.
World Flealth Organisation, Evaluation  of certain food additives and contaminants,3gth
Report of the Joint FAOAMHO  Expert Committee on Food Additives, WHO Technical
Report Series No 828, WHO, Geneva,  1992.
Scientific  Committee for Food, European Commission,  'Alginates',  Minutes of the 75th
Meeting of the Scientific Committee for Food held on 11-19 October 1990 in Berlin,
Document  III|92I2/90,  European Commission DG III, Brussels,  1990.
World Flealth Organisation,  Evaluation  of certain food additives and contaminants, 4lst
Report of the Joint FAOAMHO  Expert Committee on Food Additives, WHO Technical
Report Series No 837, WHO, Geneva,  1993.
Scientific Committee for Food, European Commission,  'Report of the Scientific
Committee for Food on a second series of food additives of various technological
functions',  Reports of the Scientific Committeefor  Food, (26th series), Office for Official
Publications  of the European Communities, Luxembourg,  1992.
Scientific  Committee for Food, European  Commission,  'Opinion on cross-linked sodium
carboxymethyl  cellulose (modified cellulose gum)', Reports of the Scientific Committee
for Food, (35th series), Offrce for Official Publications of the European Communities,
Luxembourg,  1996.
European Parliament and Council Directive 94l35lEC of 30 June 1994 on sweeteners for
use in foodstuffs, OJ L 237, 10.9.1994, pp. 3-12.
Joint FAO/WHO Expert Committee on Food Additives, Toxicological evaluation of
certainfood additives,  WHO Food Additives  Series No 10, WHO, Geneva,  1976.
Scientific Committee for Food, European Commission,  'Report of the Scientific
Committee  for Food on extraction solvents', Reports of the ScientiJic  Committee  for
Food, (|[th series), Office for Offlrcial Publications of the European  Communities,
Luxembourg, 1981.
McCurdy D.K., Schneider, B. and Sheie, H. G., 'Oral glycerol: The mechanism  of
intraocular hypotension', American Journal of Ophthalmology,6l,1966,  1244-9.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
Reports of the Scientific  Committee  for Food (43rd  series)47.  Reynolds, J.E.F. (ed.), Martindale: the extra pharmacopoeia, 31st edition, Royal
Pharmaceutical  Society.  London,  1996.
48.  Kwitko, M. L., 'The pediatric  glaucomas',  International Ophthalmology Clinics, 21,
1981, 199-222.
49.  Bartlett, J.D., 'Adverse effects of anti-glaucoma  medications', Optometry Clinics, l,
1991, 103-26.
50.  Kugler, K.K., Dick, A. R. and Nelson,  S. R., 'Intraocular and intraventricular  pressures
after glycerol ingestion'  , Archives of Neurologt,34,  1977 , 451.
51.  Oakley, D. E. and Ellis, P. P., 'Glycerol and hyperosmolar non-ketonic coma' , American
Journal of Ophthalmologt,  81, 197 6, 469-7 2.
52.  Freund,  G., 'The metabolic effects of glycerol  administered  to diabetic patients' Archives
of Internal Medicine, 121, 1968, 123.
53.  IDACE  'Additional information  on sodium-L-ascorbate', CS/ADD/MsAd/155,  December
Iggl,unpublished  submission  to the Scientific Committee for Food, Paris.
54.  Commission Directive  96l5lEC on cereal based foods and baby foods, OJ L 49,
28.2.t996,pp. 17-28.
55.  Scientific  Committee for Food, European Commission,  'Opinion on additives in nutrient
preparations  for use in infant formulae, follow-on formulae and weaning foods', Minutes
of the 103rd Meeting of the Scientific  Committee for Food held on 19 and 20 September,
Annex IV to Document 11115693196, European Commission DG III, Brussels,  1996.
56.  Commission Directive 96l4lEC of 16 February 1996 amending  Directive 9ll32llEEC  on
infant formulae and follow-on formulae, OJ L 49,28.2.1996, pp. 12-16.
57.  Scientific Committee for Food, European Commission, 'Opinion of the Scientific
Committee for Food on diacetyltartaric acid esters of mono- and diglycerides (DATEM E-
472e), expressed  on 13 June 1997', Minutes of the l07th meeting of the Scientific
Committee for Food, 12-13 June 1997.
Reports of the Scientific  Committee  for Food (43rd series)J.
AN ADDITIONAL  LIST OF MONOMERS  AND ADDITIVES
USED IN TIIE MANUFACTURE OF PLASTIC  MATERIALS
TNTENDED TO COME INTO CONTACT  WITII FOODSTUFFS
(expressed on 13 June 1997)
During its 73rd meeting, the SCF was informed that, in principle, it  was the
Commission's  intention to submit for adoption, at every meeting,  a list of substances
(monomers  and additives) used in the manufacture  of plastic materials and articles
intended  to come into contact with foodstuffs,  evaluated  or re-evaluated  by the Working
Group 'Food contact materials  (FCM)' of the SCF (SCF-WG) between each plenary
session of the SCF.
This document  contains the evaluations  on monomers  (Annex 2) and on additives (Annex
3) adopted by the SCF-WG on FCM during the 69th (26-28 February 1997) and the 70th
meetings (20-23 May 1997). The polymeric  additives  were excluded  because  they will be
added in a specific  report submitted  later.
The substances  are listed in alphabetical  and PM/Ref. No order and the allocation into the
various SCF lists is summarised  in Annexes 4 and 5. The column headed 'Explanation'
gives, for the substances  for which the SCF-WG changed a previous classification, a brief
explanation  for the reason for the change.
4.  The SCF endorses the evaluations given by the SCF-WG during the abovementioned
meetings. As a memo, the definition of the different lists established by the SCF is
included  in Annex 1.
Because other additives are now under exarnination and will probably  be evaluated in a
few meetings,  the Commission services  intend to postpone the publication  of the
evaluations  given in this document until the remaining  substances have been evaluated.
However, the evaluations  of this document will be communicated  to the interested parties
(governrnents, profes si onal org anisation  s etc. ).
It has to be stressed that the SCF-WG classified these  substances  according to the general
criteria described in the document  CSIPM/LI47 without any exception  and that these
general criteria have already been endorsed by the SCF in the past.
Note
This is the first report distributed  on the Internet and therefore some changes have been made
compared  to the previous reports. In fact until now the reports did not contain  any substance
classified  by the SCF-WG in SCF-lists 7-9, because  the management of these lists was delegated
to the SCF-WG.
5.
6.
64 Reports of the Scientilic Committee  for Food (43rd  series)To avoid any misunderstanding,  for the first time this report contains  all the substances  classified
by SCF into SCF-lists  0-6 and also the substances  classified  by the SCF-WG into lists 7-9.
It has been noted that the SCF-WG classified into SCF-lists 7-9 during the 69th and 70th
meetings the following substances: 15030 (rnonomer)  and 38565147540176665183598  (additives).
The polymeric additives were excluded because they will be added in a specific  report to be
submitted later for the approval of the SCF. The current classification of these polymeric
additives made by the SCF-WG  during the 70th meeting (in meeting 69 no polymeric additive
was examined) can be found in the minutes of these meetings, which will be issued only after
confirmation by the SCF-WG (probably after 15 october 1997).
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DEFINITION  OF THE SCF LISTS
Substances for which the Committee  was able to express an opinion
List 0
Substances,  e.g. foods, which may be used in the production of plastic materials and articles, e.g.
food ingredients  and certain substances  known from the intermediate metabolism in man and for
which an ADI need not be established for this purpose.
List 1
Substances,  e.g. food additives,  for which an ADI, a temporary  ADI (I-ADI), an MTDI, a PMTDI,
a PTWI or the classification 'acceptable' has been established by this Committee or by JECFA.
List 2
Substances  for which a TDI or a t-TDI has been established bv this Committee.
List 3
Substances  for which an ADI or a TDI could not be established,  but where the present use could
be accepted.
Some of these substances  are self-limiting because  of their organoleptic properties or are volatile
and therefore  unlikely to be present in the finished product. For other substances with very low
migration, a TDI has not been set but the maximum level to be used in any packaging material or
a specific limit of migration  is stated. This is because  the available toxicological data would give
a TDI which allows that a specific limit of migration or a composition  limit could be fixed at
levels very much higher than the maximum likely intakes  arising from present uses of the
additive.
List 4
Section 4A (for monomers)
Substances for which an ADI or TDI
substance migrating into foods or in
method.
could not be established,  but which could be used if the
food simulants is not detectable bv an asreed sensitive
Reports of the Scientific  Committee  for Food (43rd  series)Section 4B (only for monomers)
Substances for which an ADI or TDI could not be established,  but which could be used if the
levels of monomer  residues in materials and articles intended to come into contact with foodstuffs
are reduced as much  as possible.
List 4 (for additives)
Substances for which an ADI or TDI could not be established,  but which could be used if the
substance migrating into foods or in food simulants  is not detectable  by an agreed sensitive
method.
List 5
Substances  which should not be used.
Substances for which there were insufficient toxicological or technological  data to enable
the Comrnittee to express an opinion
List 6
Substances  for which there exist suspicions  about their toxicity  and for which data are lacking or
are insufficient.
The allocation of substances  to this list is mainly based upon similarity of structure  with that of
chemical substances already evaluated or known to have functional groups that indicate
carcinogenic  or other severe toxic properties.
Section 6A
Substances  suspected  to have carcinogenic properties. These substances  should not be detectable
in foods or in food simulants  by an appropriate  sensitive method for each substance.
Section 6B
Substances
indicated.
List 7
Substances
established.
suspected to have toxic properties (other than carcinogenic).  Restrictions  may be
for which some toxicological  data exist, but for which an ADI or a TDI could not be
The required  additional information  should be fumished.
rts of the Scientific  Committee  for Food (43rdList 8
Substances  for which no or only scanty and inadequate data were available.
List 9
Substances  and groups of substances  which could not be evaluated  due to lack of specifications
(substances)  or to lack of adequate  description (groups of substances).
Groups of substances  should be replaced, where possible, by individual substances  actually in use.
Polymers  for which the data on identity  specified  in 'SCF Guidelines'  are not available.
ListW
'Waiting list'. Substances  not yet included in the Community  lists, as they should be considered
'new' substances, i.e. substances never approved at national level. These substances  are not
susceptible to be included  in the Community lists, lacking the data requested by the Committee.
On the basis o1'the data lackine the waitine list is subdivided into:
List W7
Substances  for which some toxicological  data exist, but for which an ADI or a TDI could not be
established. The required  additional information  should be furnished.
List W8
Substances  for which no or only scanty and inadequate data were available.
List W9
Substances  and groups of substances  which could not be evaluated  due to lack of specifications
(substances)  or to lack of adequate  description (groups of substances).
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DEADLINES  FOR THE TRANSMISSION  OF TOXICOLOGICAL  DATA
List 2
List 6
List 7
List 8
List 9
Data on:
- 
hydrolysis
- 
mutagenesis
- 
migration
Studies:
- 
28-days
- 
90-days
- 
reproduction
- 
teratogenesis
- 
long-term
For substances  for which a temporary TDI (t-TDI) has been fixed,
the data shall be transmitted as soon as possible.
1 year after the evaluation of SCF*
NB: The deadlines for the transmission  of the results of the tests
requested are the same of those indicated  for list 7.
1 year after the evaluation of SCF*
2 years after the evaluation  of SCF
2 years after the evaluation of SCF
2 years after the evaluation of SCF
2 years after the evaluation of SCF
2 years after the evaluation of SCF
3 years after the evaluation of SCF
3 years after the evaluation of SCF
5 years after the evaluation of SCF
I year after the evaluation  of SCF*
N.B. The deadlines for the transrnission  of the results of the tests
requested are the same of those indicated  for list 7.
1 year after the evaluation  of SCF
The dates labelled with an asterisk refer to the time inside which the Commission has to
receive a letter in which the interested person declares  his/her intention to transmit  the
requested  data and encloses, for example,  a copy of the contractual  engagement with the
laboratory(ies) of analysis.
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LIS'T OF MONOMERS  EVALUATED IN THIS REPORT AND THEIR
CLASSIFICATION
| | 1245, 021 56-97 -0  : ACRYLIC
.  :  IACID.
,DODECYL .:
'  ,  TESTER
:
:
l
:
-"  '  "'_"  :l 
_
125781-
,R: 0.05 mg/kg of food.
;Available: migration  data, three
. (negative)  mutagenicity studies.
,(ISS/TNO  SDS, March  1997 :
iCS/PIW2996lIl245).
i
rRemark:  since high migration  into
rfat has been demonstrated  the WG
:recommends that the Commission
rtake the necessary  measures so that
rthe restriction proposed is not
.exceeded.
iS"Uiiu"". *tti.tt tttould notbe 
"r.4.
:
,Available:  inadequate migration
:data, acute toxicity data on several
:components of mixfure.
:
,Evaluation is not possible  from the
,data provided. Sources for the
:mixture mentioned  do not exclude
,presence  of toxic components.
,Quantitative ranges are lacking for
.many substances.
:(RIVI\4/TNO  SDS, February 1997 :
,cslPMl2993lt2578).
.ALKYL(C1-
.C4)PHENOLS
,(consisting  of a
,mixture of
:mono-, di-, tri-
,and tetra-alkyl
,substituted
rphenols and up
,to 2 Yo phenol)
:5
:
:
i
!
I
i
:
:
i
]
i
:
:
:
:
:Transferred
,from SCF list
18 to list 3
,because new
'data were
,available.
i
REF.
No
CAS No NAME SCF
List
SCF OPINION EXPLANA.
TION
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No
CAS No NAME SCF
List
SCF OPINION EXPLANA.
TION
1 3 780'0242s -7 e-t, 
lSro*EDroL a-
:  ,BIS(2,3 EPOXY
,  ipROpyL)
:ETHER
15030 0093 l-884 :*CYCLO-
:  :OCTENE
_: _ "_ " "" _'
15780 :00111-90-0 DIETHYLENE-
GLYCOL
MONOETHYL
ETHER
4A :Genotoxic similar to glycidylethers.
l(CS/PM/2958).
iRe-examined
,because in the
,previous
,evaluation
,was classified
,on the basis of
:the similarity
:to the
:BADGE.  The
,previous
:classification
,has been
:confirmed but
'the 
reason  was
'changed 
from
,'similar to
,BADGE'into
,'similar to
:glycidy-
,lethers'.
W7 rAvailable: inadequate migration
,data, three (negative)  in vitro
; mutagenicity studies.
:Needed: detailed  information  on the  ,
:analytical method  for the
,determination  of cyclo-octene  in
iaqueous food simulants,  particularly  ,
ron establishment  of detection  limit.
:Migration  experiments  should be
;carried out with blends of polymer
:with maximum concentration  of 
:
'Vestenamer.
:(RIVM/TNO  SDS, February 1997 : 
'
; QS-4P_M/2  5 2-? REV II/ I I 0-3, 0_)l
2  :Group I-TDI: 0.05 mglkg b.w. (with 'Confirmed.
:16993:53765,16996:53820,  :
',16999,17002:53860,30120, 
.
'48030).
:See references for 16996.
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No
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List
SCF OPINION EXPLANA.
TION
1 66e0, 0r32r-7 4-0, l?Y]ryY! ,  :BENZENE
. 19990 :00079-39-0  TMETHACRYL
.  .  ,AMIDE
6,4. ,R: not detectable in food. Confirmed in 
' list 6,4. but the  ,
Available:  two (negative)  Ames tests;data requested
and a mouse inhalation studv have been
showing  weak clastogenic  activity. :modified.  See
Needed: detailed description of  ,the SCF
analytical method to determine  opinion.
residual  content.
(RIVIWTNO SDS, January  1995 =
cstPul2572).
(tss sDS, 1997:
cslPM/29591r6690). l
:4A
j
:
:
:
a
a
:Remark:  for the toxicity part (based
,on very low migration)  there is no
rneed to ask for further data (awaiting
;the needed non-tox data to be listed
:ig Liqt,4A-),
:The classification is based on the
rdecision  made on the structurally
, related compound  acrylamide
;classif,red  in List 4A and because  it
;is not detected in food/food
isimulants.
i
,Available: migration  data, Ames
;test, dominant lethal assay,
: two generation  reproduction study,
rteratogenicity  study in mice and
, three neurotoxicity  studies.
i(RIVM/TNO  SDS, November  1996
: CS/PM/2961).
,Transferred
,from List 6A.
:to 4,A' on the
:basis of the
rstructurally
rrelated
:cornpound
;acrylamide,
:classified in
jList 4A..
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LIST OF ADDITIVES EVALUATED  IN THIS REPORT AND THEIR
CLASSIFICATION
30120 i00111-15-9:ACETICACID,  . 3  ,R: 3 mglkgof foodbasedonthe  ,Confirmed.
2-ETHOXY  group I-TDI: 0.05 mg/kg b.w. for
ETHYL ESTER  iI6996.
38565 ,90498-90-1  *3,9-BIS(2-(3-  W7 ,Available:  migration  data, three 
,
:  ,(tert.BUTYL-4- ',  rmonth oral rat study, three
..HYDRoXY-5-.'..(negative)inv[tromutagenicity ,METHYL  1studies, high bioaccumulation
,  :PHENYL)PRO ,  ,potential.
PTONYLOXY)-
rtert.BUTYL)- ,  :Needed: data demonstrating  absence
,  TTETRAOXA .  ;especially  in liver and fat.
SPrRO(5.5)trN (R]VM SDS,:
DECANE
39090 ,-  ,N,N-!I!!?_ : 2  ;Group t-TDI: 0.02mgkgb.w. (as  Confirmed but
:HYDROXY ,  ','free'amine) (with 39120).  the needed
.  :ETTIYL)ALKYL :  .See references for 39120.  data have
(C8-CIS) AMINE  Needed: three in vitro mutagenicity  been
.  studies according  to guidelines on  , specified.
i  ,  ;::T_.:f[l.f.No  3e0e0 or 3e120).
,:
:Remark:  on the basis of the
,available studies it remains included
:in the group I-TDI pending  the
,results of the required  mutagenicity
,studies. If negative it will be
:classified in List 3 with a restriction
,of 5 mg/kg of foo-{,,
REF.
No
CAS No NAME SCF
List
SCF OPINION EXPLANA-
TION
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No
CAS No NAME SCF
List
SCF OPINION EXPLAIIA-
TION
4s4s0:68610-st  t iB;"#Jrt# 
:
i  :PENTADIENE-  i
'  ,ISOBUTYLENE  .
COPOLYMER
:
.i
.. :  .. .. .. ..  ..
47 540 :27 458-90-8  i *OI-
:fri!3:FB?
:
i'  _  "'_"  " -_ -  l'_
. 48030, 001 12-34-5  i DIETHYLENE-
.  :  ,GLYCOL
i  i  iMONOBUTYL
.ETHER
':
l+gOSO i001 1 l-90-0 :nmrrrYrENE- .  .  ;GLYCOL
:
.  i  :MONOETHYL
I  :  iETHER
3  ,R: 5 mglkg of food.
;Available: Migration data, four
;(negative)  in vitro mutagenicity
:studies, 28-day  and 3-month oral rat
i studies, possible bioaccumulation
,potential.
:(RIVM/TNO  SDS, May 1997 :
' 
CS/PM/2802 REV 1145450).
,
iRemark: despite the indication of
i possible  bioaccumulation (i.e. log
rPo/w >4) the WG finds the
;substance  acceptable for the use as
idescribed under 3.1 of the document
'(e.g. 
in ABS for freezers or very
:short contact).
W7 ,AvailuUi., uA.quut. -igrutioo  duiu,
ithree (negative) in vitro
;mutagenicity studies and a 4-week
;oral rat study on a closely related
; compound  (di-tert-dodecyl
ipentasulfide).
,Transferred
lfrom SCF list
i7 into list 3
ibecause  new
:data were
iavailable.
)
j
:
:
:
:
i
i
i
i
iNeeded: the information  provided is i
iinsufficient  to understand the 
,
iprocedure  for the determination of
:the purity of the di-tert-dodecyl 
i
idisulphide. Information  on the 
,
;method of quantification  is missing. 
,
i (RIVM/TNO  SDS, December
i ! ee6 : CSf M1z?94_), 
.
2  lGroup I-TDI: 0.05 mglkg b.w. (with iConfirmed.
i 1 5780:48050,  16993:537 65,
j16996:53820,r6999,  '
;17002:53860,30120,48050). 
;
..S-,"-q.{,q-f..{gl-q.es,-to.-{.-{699Q1 .  i
2  iGroup t-TDL 0.05 mglkg b.w. (with iConfirmed.
i15780:48050,16993:53765, 
. ,16996:53820,16999, 
'
i:17002:53860, 30120,48030).  l
. ... .Sg.,g 1e-{_g1-encgs-for 16996, 
,
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No
CAS No NAME SCF
List
SCF OPINION EXPLANA.
TION
,76665 *POLYCYCLO
OCTENE
:
--  -  -":i
83598  : 181314-48- ,*Reaction  i :J  :product  of 3-  i
:r  THYDROXY-  i
.  rtert.BUTYL  i
:  ,BENZOFURAN i
' 
t-2-oNE 
w1!h
,  JOXYLENE  : i  :consisting  of
i  ,s,'l-DI- 
I
I  :tert-BUTYL-3-  :
i  ,(2,3-DIMETHYL  ,
i  1PHENYL)-(3H)-:
,  ,BJ|_IIFURAN 
i
,  ,-2-ONE  .
:l.|ID_ l-l-?rJ*  I
,  ,BUTYL-3-(3,4- 
',, .  :3,1YRHIL",  .
BENZOF UNEN
Awaiting data on the monomer  with  r
PM/Ref. No 15030) 
i
,Needed: migration of monomer  from,
relevant plastic materials.
i(RIVM/TNO  SDS, February 1997 : 
,
:CS/PM/2995176661).  i
'Remark: migration of this polymeric
,additive is covered by the limit for
iglobal migration. No need for
bioaccumulation data, since no
effects were seen in the
ilymphonodes  and Kupfer cells in the,
90{ay study.
;Available:  Adequate migration data,'
,three (negative)  in vitro
'mutagenicity 
studies, 90-day oral rat
lstudy (including  examination of the 
:
iactivity of the peroxisome  associated:
;enzymes), metabolism studies (in  .
vitro and in vivo) and an in vitro
,gene mutation assay in bacteria with
:the dimer, high bioaccumulation 
.
potential.
Needed: data demonstrating  the
:absence  of bioaccumulation in vtvo.
:(RIVM/TNO  SDS, Dcember 1996:  ,
cs/PM12965l83s98).
w7
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LIST OF MONOMERS  EVALUATED  IN THIS REPORT
AND THEIR CLASSIFICATION
REF
No
CAS No NAME SCF
List
tt24.5_ .t02ll6-97:9
12578',-
t,
:
13780 ,02425-79-8
:i-  -..'
15030 i00931-88-4
tsiso loor r r-eg-s
16690 :0,1.3-21-74 0
19990 .00079-39-0
:-AC.RYLIC_  A-CrD2,DO,DECYL.PSTER  j
iALKYL(C1-C4)PHENOLS (consisting of a mixture of 
.
jmono-, di-, tri and tetra-alkyl  substituted phenols  and up to 
:
:1.,4rBQT_A-NEPIO-LB"rQ(2,3.:.EP-O4Y--PBO-"P-^*vL_)ETHER..1
.
,.*GYCLO-OCTENE .  l
IDIETHYLENEGLYCOL  MONOETHYL ETHER  .
.
l i*DIVINYLBEN-ZENE  l
jMETHACRYLAMIDE
a
J
5
iA
w7
2
6A
4A
ANNEX 5
LIST OF ADDITIVES EVALUATED  IN THIS REPORT
AND THEIR CLASSIFICATION
3.0l2.q]00l11.:15..?..ACPTICACI-.D:2:ETHoXY*E'T'H
38565 :e04e8-e0-1 tllf:-BjlJ1-_tl(,-:".BUrYL-4-HYDRoxY-s- ,  w7
i  ,METHY!|EENYL)PROPIONYLOXY)-tert.BUTYL)-
t...
Jeqe0 i:  .  N,N-Brs(2rtlypRo_-{yErtr-Y.L)AI.Ky_L(cq:c18)4\4rNE  :  2
4s4t0 68610 5r t 
83ff:9il3i.".toTENrADIENE 
ISoBUTYLENU , 
3
41 s!9, 27 4 s 8_:e 0.-.9,.1 DI :t9I!: D oD E_QY,L_ pI S-UL PHI DE
-4 
S-0 1 0 ; 0 0. J .1-2 1! 4 -s : D-r ETH yL E NEGLY C O L MON-O, 
-B-UTY*L_.E IHES. . .
48050 .OO1 I 1-90-0 DIETHYLENEGLYCOL  MONOETHYL  ETHER
7e,a,6'i'- 
' i;Vorvcvdlo-ocrEi{E
83se8:rsiti+-+8tt',fi11;t"ln*:;-"ji#;,lro3*;1ft3'.J:Ti,"'Yil1
w7
2
2
w7
REF.
No
CAS. No NAME SCF
List
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2.
CLARIFICATION  AND EXPLANATION OF TIIE
SCF's OPINIION  OF 7 JUNE 1996 ON BADGE
(expressed  on 13 June 1997)
Since the Committee  expressed its opinion on BADGE on 7 June 1996 (SCF, 40th series of
reports, I99l), a request by the Commission has now been received to provide a more detailed
explanation  of the following items:
the background of the change in the classification  from SCF list 4 to list 7, with special
emphasis on the mutagenicity data;
the characterisation of the identity of the hydrolysis  products, which are included in the
upper limit of I mg/kg of food as a temporary restriction for speciflrc  migration of BADGE
and its hydrolysis products.
The change in the classification  from SCF list 4 to list 7, with special emphasis  on the
mutagenicify data
RIVM evaluation (Doc. CS/PM/L}, February, 1987):
The following studies formed the basis of the first evaluation on BADGE delivered  by the WG:
Salmonella  reversion  assay (Ames test) Posit VE I
Gene mutations  in mouse lymphoma cells Posit VE (2\
Chromosornal  aberrations in Chinese hamster bone marrow  iru
vivo
Negative* (3)
Nuclear anomalies in Chinese hamster bone marrow in vivo Nesativet G\
Chromosomal  aberrat ons n mouse sperrnatogonra tn vryo Nesative (5)
Chromosomal  aberrat ons n mouse spelmatogorTra  tn vtvo Eouivocal (6)
Chromosomal  aberrat ons n mouse spermatocytes in vivo Neeative (7)
Dominant lethal test in mouse Negative (8)
* results negative but the study had a limited experimental  design
The data evaluated showed a mutagenic  potential in vitro, but were inadequate to demonstrate  the
lack of activity in vivo,because of limitations  of the studies on somatic cells (3, 4). The genotoxic
profile was judged to be similar to that displayed by other glycidyl ethers. Therefore, in view of
Reports of the Scientific  Committee  for Food (43rd series)the carcinogenicity of some glycidyl ethers, the substance was classified as a suspected
carcinogen  (SCF list 4).
First updated evaluation on BADGE  (SCF opinion  7 June 1996, 40th series of reports).
For this updated evaluation  some additional mutagenicity studies were considered in the technical
document prepared by the WG on BADGE (CS/PM12787).
Test for the induction of unscheduled DNA synthesis in
vitro. in human white blood cells
Negative (e)
Test for the induction of structural  chromosomal  aberrations
in rat liver cells in vitro
Positive (10)
Test for neoplastic  transformation in vitro in baby hamster
kidney cells
Positive (r r)
Micronucleus test in female B6D2F1 mice Neeative (12\
Analysis of DNA single strand breaks in rat liver cells after
sinele oral administration
Negative
(13)
BADGE was evaluated  as mutagenic in vitro, and negative in in vivo studies which were again
judged as insufficient to demonstrate  lack of activity on somatic cells (because of the limited
experimental design of the studies described in (3) and (4), or because the fuIl data were not
available for independent  evaluation as for (12) and (13), but were only quoted in the form of
summaries in a review, (14)). Therefore, further in vivo studies (chromosomal aberrations  in bone
maffow and DNA damage  in liver) were requested.
Metabolic  data provided  evidence  for extensive and rapid metabolic  detoxification,  and a more
recent DNA binding study showed very low covalent binding to skin DNA after topical
application  (15). Accordingly it was expected that the genotoxic activity of BADGE in vivo
would be weak, or non-existent, Consequently, BADGE was provisionally reclassified in list 7
(SCF opinion, 7 June 1996).
Since, the opinion  on BADGE of 7 June 1996 the full reports of the studies (12, 13) have been
made available  and were considered by the WG (CS/PM/2967, February 1997). The data showed
absence of mutagenic  activity in liver and bone manow  in vivo.
Reports of the Scientific  Committee  for Food (43rd series)Characterisation of the identity of the hydrolysis products, which are included in the
upper timit of 1 mg/kg of food as a temporary restriction for specific migration of
BADGE and its hydrolysis  products
In order to reach a view on which hydrolysis products should be included in the upper limit of 1
mdkg of food as a temporary restriction  for BADGE and its hydrolysis  products, the following
substances  have to be considered:
BADGE
monoadduct,  in presence  of water and acid:2-(4-(2,3-epoxypropanyloxy)  phenyl)-2-(4-
(2, 3 -dihydroxypropanyloxy)phenyl)  propane
diadduct  : 2,2-bis(4-(2,3-dihydroxypropanyl)phenyl)propane
monoadduct  of BADGE with HCI
diadduct  of BADGE with HCl
Recent and ongoing studies have shown that the following substances  can be found in the
coatings, foodstuffs and simulants :
Coating:  A, D, E (D, E in some special coatings)
Foodstuffst A, B, C (A -+ B + C) and D, E (as migrants from special coatings)
Simulants:  A, B, C (A -+ B + C)
The Committee noted that in coatings residual amounts of compound A and, depending  on the
type of coating, also the compounds  D and E have been detected. Analyses  have shown that these
residuals A, D and E may migrate into any type of food whether aqueous or fatty. Compound  A
has been shown to hydrolyse in aqueous foods to B and subsequently  to C. However,  in fatty
media compound A is stable. If food contains chloride ions, it is theoretically possible  that
compound  A may be transformed  into compound  D and subsequently E.
The Committee therefore  recommends  as follows on which substances should be included in the
limit for BADGE and its hydrolysis  products. There is some experimental evidence  that
compound  C rnay be of minor toxicological  relevance  and therefore  need not be considered when
assessing  compliance of foodstuffs with the SCF group restriction.  Consequently,  determination
of compliance with the SCF group restriction would require that only the sum of A and B be
considered  in the case of examination of foodstuffs. However, in the case of examination of food
contact materials by aqueous  food simulants, the sum of A, B and C should be determined,
because in this case more A and B would be converted to C as compared  with the situation in
foodstuffs.
Reports of the Scientific  Committee  for Food (43rd  series)The compounds  D and E in foodstuffs  are of concern  because of their structural analogy to the
genotoxic monochloropropanediol (MCPD). The Committee will address this issue as soon as it
has confirmation of their presence  and their levels in food.
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